PRODUÇÃO DE GLICOLIPÍDIOS

A genetically modified non-pathogenic cell enhances rubiwettin production efficiency and safety, addressing consumer concerns and cost issues in biosurfactant production by expressing specific enzymes for higher yields and safer biosurfactant production.

BR112025024180A2Pending Publication Date: 2026-11-10EVONIK OPERATIONS GMBH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
BR112025024180
Authority / Receiving Office
BR · BR
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-11
Filing Date
2024-05-02
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Current methods for producing biosurfactants like rubiwettins using pathogenic organisms are limited by consumer safety concerns and high production costs, and existing non-pathogenic methods do not achieve sufficient yield and efficiency for large-scale surfactant replacement.

Method used

A biotechnological method using a non-pathogenic cell genetically modified to express specific enzymes (E1 and E2) for converting carbon sources into glycolipids like rubiwettins, with enhanced enzyme activity through heterologous expression, allowing the production of safer and more efficient biosurfactants.

Benefits of technology

The method enables higher product yields, safer production, and reduced costs by using non-pathogenic cells that can produce rubiwettins with defined properties and improved space-time yields, overcoming the limitations of pathogenic methods.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to a microbial cell for producing at least one lipid with general formula (II) from at least one carbon substrate, wherein R1 and R2 independently of one another comprises identical or different organic radicals each with 5 to 13 carbon atoms, wherein the cell is a non-pathogenic cell that is genetically modified to increase the heterologous expression relative to the wild-type cell of: - Enzyme E1 a 3-(3-hydroxyalkanoyloxy)alkanoic acid (HAA) synthase comprising SEQ ID NO: 1, SEQ ID NO: 7, SEQ ID NO:11, SEQ ID NO: 15 or a variant thereof, wherein the variant comprises 60% sequence identity to SEQ ID NO: 1, 7, 11 or 15; and - Enzyme E2 a glycosyltransferase (EC 2.4) comprising SEQ ID NO: 2, SEQ ID NO: 8, or SEQ ID NO: 12, or a variant thereof, wherein the variant comprises 60% sequence identity to SEQ ID NO: 2, 8 or 12.
Need to check novelty before this filing date? Find Prior Art

Description

1 / 49 “PRODUCTION OF GLYCOLIPIDS” FIELD OF THE INVENTION

[001] The present invention relates to a recombinant cell and a biotechnological method for the production of glycolipids. In particular, the cell is a non-pathogenic cell genetically modified to produce at least one glycolipid. BACKGROUND OF THE INVENTION

[002] Currently, most of the surfactants available, such as Lauryl Ether Sodium sulfate (SLES), betaine, and similar surfactants are chemically produced on an industrial scale. These chemically produced surfactants exhibit all the disadvantages normally associated with chemical production processes, such as the formation of harmful byproducts. For example, the production process of SLES generates at least one harmful byproduct: 1,4-dioxane. With the aim of reducing the amount of toxic products generated and considering the growing consumer demand for environmentally sustainable products, there is a general trend towards the production and use of biosurfactants. In addition to producing fewer toxic byproducts during the manufacturing process, biosurfactants also exhibit useful properties such as high structural diversity, beneficial surfactant properties, low environmental toxicity, antibiotic or bioactive properties, and complete biodegradability.There is, therefore, a general push towards the production and use of biosurfactants as a replacement for chemical surfactants.

[003] Rubiwettins, a group of glycolipids, are an example of this type of biosurfactant. Rubiwettins represent an economically interesting class of surfactants, as they can potentially replace chemically produced surfactants.

[004] Rubiwettins are exolipids composed of a β-D-glucose molecule linked to a 3-hydroxy fatty acid dimer, with hydroxylated fatty acid chains between C14 and C8 as the main lipid components. They possess surfactant properties. Currently, rubiwettins are being synthesized by Petition 870250101536, dated 06 / 11 / 2025, pages 120 / 174 2 / 49 a wild isolate of Serratia rubidaea, which is a human and animal pathogen. The fact that this production organism is capable of causing disease considerably reduces consumer acceptance of conventionally produced rubiwettins. Furthermore, more stringent safety requirements are also necessary during the rubiwettin production process, which increases costs due to higher capital investment and possibly the inclusion of additional production steps.

[005] Currently available methods for the production of biosurfactants, such as rubiwettins, involve the use of these pathogenic organisms. Production yield can be optimized by varying pH, oxygen supply, medium composition, feeding strategies, nitrogen supply, temperature, substrate selection, and similar factors. However, if rubiwettins are to be used on a large scale as surfactants, they will have to compete with currently used surfactants. The latter are basic chemicals that can be produced at a very low cost. Therefore, rubiwettins must also be produced at the lowest possible cost, without risks to consumer health, and with properties defined to the greatest extent possible. This is not possible solely through the optimization of performance parameters via process optimization.

[006] Patent WO 2019 / 154984 discloses a non-pathogenic cell genetically modified to introduce specific enzymes capable of producing rubiwettins from a carbon substrate. However, there is still a need in the field for a more efficient alternative method for the production of rubiwettins, with even higher product yields. DESCRIPTION OF THE INVENTION

[007] The present invention seeks to solve the problems mentioned above by offering a biotechnological means of producing biosurfactants, such as lipids, especially rubiwettins, from a carbon source using a non-pathogenic cell. In particular, the non-pathogenic cell can be genetically modified. Petition 870250101536, dated 06 / 11 / 2025, pp. 121 / 174 3 / 49 modified to increase the expression of at least one enzyme (E2) capable of converting 3-hydroxyalkanoyl-3-hydroxyalkanoyl-CoA / ACP and / or 3-(3-hydroxyalkaneoyloxy)alkanoic acid (HAA), in combination with NDP-glucose, into β-D-glucopyranosyl-3-hydroxyalkanoyl-3-hydroxyalkanoate, wherein the enzyme E2 is a glycosyltransferase (EC 2.4) comprising SEQ ID NO: 1, SEQ ID NO: 7, SEQ ID NO: 11 or SEQ ID NO: 15, or a variant thereof. The genetically modified cell can then be used to convert a suitable carbon source into a lipid with the general formula II shown below: General Formula II wherein R1 and R2, independently of each other, are identical or different alkyl groups with 5 to 13 carbon atoms. In particular, the alkyl group may be saturated or unsaturated. More specifically, the alkyl group of R1 and / or R2 may be a saturated alkyl radical. Even more specifically, R1 and / or R2 may be selected from the group consisting of pentyl, heptyl, nonyl, undecyl, tridecyl and (CH2)n-CH3, with n ranging from 4 to 12.

[008] In particular, the cell can be further genetically modified to increase the expression of at least one enzyme (E1) capable of converting 3-hydroxy-alkanoyl-CoA / ACP into 3-hydroxy-alkanoyl-3-hydroxy-alkanoyl-CoA / ACP and subsequently into 3-(3-hydroxy-alkanoyloxy)alkanoic acid (HAA), and the enzyme E1 can be a 3-(3-hydroxy-alkanoyloxy)alkanoic acid (HAA) synthase comprising SEQ ID NO: 1, SEQ ID NO: 7, SEQ ID NO: 11, SEQ ID NO: 15, or a variant thereof.

[009] The cell, according to any aspect of the present invention, can be Petition 870250101536, dated 06 / 11 / 2025, pp. 122 / 174 4 / 49 capable of producing rubiwettins from a carbon source using a non-pathogenic cell.

[010] This lipid of General Formula II is also called a glycolipid and, more specifically, a rubiwettin or a glycolipid. The genetically modified cell, according to any aspect of the present invention, has the advantage of being non-pathogenic and easy to cultivate. This makes the cell safer for production and reduces costs, since no special safety requirements are needed in the laboratory during the production and use of rubiwettins. The cells, according to any aspect of the present invention, have the additional advantage of being able to use a variety of carbon substrates to produce the lipids according to any aspect of the present invention. For example, simple carbons such as glucose can be used as a carbon substrate. Furthermore, the lipids formed according to any aspect of the present invention have defined and flexible properties.An additional advantage is that rubiwettins can be produced with higher space-time yield, higher carbon yields, higher product concentration, and greater product homogeneity (fatty acid species), compared to cells without enhancement of these activities.

[011] According to one aspect of the present invention, a microbial cell is provided for the production of at least one lipid having general formula II from at least one carbon substrate, General Formula II where R1 and R2, independently of each other, comprise radicals. Petition 870250101536, dated 06 / 11 / 2025, pp. 123 / 174 5 / 49 identical or different organic compounds, each with 5 to 13 carbon atoms, in which the cell is a non-pathogenic cell genetically modified to increase heterologous expression, relative to the wild-type cell, of: - Enzyme E1: a 3-(3-hydroxy-alkanoyloxy)alkanoic acid (HAA) synthase comprising SEQ ID NO: 1, SEQ ID NO: 7, SEQ ID NO: 11, SEQ ID NO: 15 or a variant thereof, wherein the variant comprises 60% sequence identity with SEQ ID NO: 1, 7, 11 or 15; and - Enzyme E2: a glycosyltransferase (EC 2.4) comprising SEQ ID NO: 2, SEQ ID NO: 6 or SEQ ID NO: 12, or a variant thereof, wherein the variant comprises 60% sequence identity with SEQ ID NO: 2, 8 or 12.

[012] In particular, glucose can be added so that one or both conversions occur. Thus, glucose can be added for the conversion of 3-hydroxyalkanoyl-3-hydroxyalkanoyl-CoA / ACP to β-D-glucopyranosyl-3-hydroxyalkanoyl-3-hydroxyalkanoate. In another example, glucose can be added for the conversion of HAA to β-D-glucopyranosyl-3-hydroxyalkanoyl-3-hydroxyalkanoate. In yet another example, both HAA and 3-hydroxyalkanoyl-3-hydroxyalkanoyl-CoA / ACP can be present at the same time for the production of β-D-glucopyranosyl-3-hydroxyalkanoyl-3-hydroxyalkanoate.

[013] The cell, according to any aspect of the present invention, can be genetically modified to increase the heterologous expression, relative to the wild-type cell, of the enzyme (E1), which is capable of converting 3-hydroxyalkanoylCoA / ACP into 3-hydroxyalkanoyl-3-hydroxyalkanoyl-CoA / ACP and subsequently into 3-(3-hydroxyalkanoyloxy)alkanoic acid (HAA). In particular, the enzyme E1 can be a 3-(3-hydroxyalkanoyloxy)alkanoic acid (HAA) synthase. In one example, the enzyme E1 comprises a sequence selected from the group consisting of SEQ ID NO: 1, 7, 11, 15 or a variant thereof. In one example, the variant of SEQ ID NO: 1, 7, 11 or 15 comprises 60% sequence identity with SEQ ID NO: 1, 7, 11 or 15, respectively.

[014] In one example, the E1 enzyme may possess the polypeptide sequence SEQ Petition 870250101536, dated 06 / 11 / 2025, pp. 124 / 174 6 / 49 ID NO: 1 or a polypeptide sequence in which up to 25%, preferably up to 20%, more preferably up to 15%, and in particular up to 10, 9, 8, 7, 6, 5, 4, 3, 2, 1% of the amino acid radicals are modified compared to the reference sequence SEQ ID NO: 1 by deletion, insertion, substitution or a combination thereof, and which still possesses at least 10%, particularly 50%, more particularly 80%, and even more particularly more than 90% of the enzymatic activity of the enzyme possessing the reference sequence SEQ ID NO: 1, wherein the enzymatic activity of enzyme E1 is understood to be the ability, preferably, to convert 3-hydroxy-alkanoyl-CoA / ACP into 3-hydroxy-alkanoyl-3-hydroxy-alkanoyl-CoA / ACP and subsequently into HAA.

[015] In another example, the E1 enzyme may possess the polypeptide sequence SEQ ID NO: 7 or a polypeptide sequence in which up to 25%, preferably up to 20%, more preferably up to 15%, and in particular up to 10, 9, 8, 7, 6, 5, 4, 3, 2, 1% of the amino acid radicals are modified compared to the reference sequence SEQ ID NO: 7 by deletion, insertion, substitution or a combination thereof, and which still possesses at least 10%, particularly 50%, more particularly 80%, even more particularly more than 90% of the enzymatic activity of the enzyme with the reference sequence SEQ ID NO: 7, wherein the enzymatic activity of the enzyme E1 is understood to be the ability, preferably, to convert 3-hydroxy-alkanoyl-CoA / ACP into 3-hydroxy-alkanoyl-3-hydroxy-alkanoyl-CoA / ACP and subsequently into HAA.

[016] In a further example, the enzyme E1 may possess the polypeptide sequence SEQ ID NO: 11 or a polypeptide sequence in which up to 25%, preferably up to 20%, more preferably up to 15%, and in particular up to 10, 9, 8, 7, 6, 5, 4, 3, 2, 1% of the amino acid radicals are modified compared to the reference sequence SEQ ID NO: 11 by deletion, insertion, substitution or a combination thereof, and which still possesses at least 10%, particularly 50%, more particularly 80%, and even more particularly more than 90% of the enzymatic activity of the enzyme possessing the reference sequence SEQ Petition 870250101536, dated 06 / 11 / 2025, pp. 125 / 174 7 / 49 ID NO: 11, where the enzymatic activity of enzyme E1 is understood to be the ability, preferentially, to convert 3-hydroxy-alkanoyl-CoA / ACP into 3-hydroxy-alkanoyl-3-hydroxy-alkanoyl-CoA / ACP and, subsequently, into HAA.

[017] In a further example, the enzyme E1 may possess the polypeptide sequence SEQ ID NO: 15 or a polypeptide sequence in which up to 25%, preferably up to 20%, more preferably up to 15%, and in particular up to 10, 9, 8, 7, 6, 5, 4, 3, 2, 1% of the amino acid radicals are modified compared to the reference sequence SEQ ID NO: 15 by deletion, insertion, substitution or a combination thereof, and which still possesses at least 10%, particularly 50%, more particularly 80%, and even more particularly more than 90% of the enzymatic activity of the enzyme possessing the reference sequence SEQ ID NO: 15, wherein the enzymatic activity of the enzyme E1 is understood as the ability, preferably, to convert 3-hydroxy-alkanoyl-CoA / ACP into 3-hydroxyalkanoyl-3-hydroxyalkanoyl-CoA / ACP and subsequently in HAA.

[018] The E2 enzyme may be able to convert 3-hydroxyalkanoyl-3-hydroxyalkanoyl-CoA / ACP into β-D-glucopyranosyl-3-hydroxyalkanoyl-3-hydroxyalkanoate. In one example, the E2 enzyme may be able to convert HAA into β-D-glucopyranosyl-3-hydroxyalkanoyl-3-hydroxyalkanoate. In yet another example, the E2 enzyme may be able to convert 3-hydroxyalkanoyl-3-hydroxyalkanoyl-CoA / ACP and HAA into β-D-glucopyranosyl-3-hydroxyalkanoyl-3-hydroxyalkanoate. In all these examples, NDP-glucose may be present, particularly to include the glucose group in General Formula II. The E2 enzyme may be a glycosyltransferase (EC 2.4). In particular, the E2 enzyme comprises SEQ ID NO: 2 or a variant thereof.The term “variant,” as used in this document, includes amino acid or nucleic acid sequences, respectively, that exhibit at least 60, 65, 70, 75, 80, 85, 90, 92, 94, 95, 96, 97, 98, or 99% identity with the reference amino acid or nucleic acid sequence, preferably including amino acids that are not essential for function—for example, the catalytic activity of a protein or the folding or structure of a molecule. Petition 870250101536, dated 06 / 11 / 2025, pp. 126 / 174 8 / 49 deleted, replaced, or exchanged by insertions, or essential amino acids are conservatively substituted so that the biological activity of the reference sequence or a molecule derived from it is preserved. The state of the art comprises algorithms that can be used to align two nucleic acid or amino acid sequences and calculate the degree of identity; see Arthur Lesk (2008), Thompson et al., 1994, and Katoh et al., 2005. The term “variant” is used synonymously and interchangeably with the term “homologous.” Such variants can be prepared by introducing deletions, insertions, or substitutions into amino acid or nucleic acid sequences, as well as by fusions comprising such macromolecules or variants thereof.In one example, the term "variant," with respect to the amino acid sequence, includes, in addition to the sequence identity mentioned above, amino acid sequences that have one or more conservative amino acid substitutions with respect to the reference sequence or the wild-type sequence, or includes nucleic acid sequences that encode amino acid sequences that have one or more conservative amino acid substitutions. In one example, the term "variant" of an amino acid or nucleic acid sequence includes, in addition to the degree of sequence identity mentioned above, any active portion and / or fragment of the amino acid or nucleic acid sequence, respectively, or any nucleic acid sequence that encodes an active portion and / or fragment of an amino acid sequence.The term “active portion,” as used in this document, refers to an amino acid sequence or a nucleic acid sequence that is shorter than the complete amino acid sequence or that encodes, respectively, less than the complete amino acid sequence, such that the amino acid sequence or the encoded sequence, respectively, retains at least part of its essential biological activity. For example, an active portion and / or fragment of a protease may be able to hydrolyze peptide bonds in polypeptides. The expression “retains at least part of its essential biological activity,” as used herein. Petition 870250101536, dated 06 / 11 / 2025, pp. 127 / 174 9 / 49 document, means that the amino acid sequence in question exhibits superior biological activity distinct from the background activity, and the kinetic parameters that characterize this activity, more specifically kcat and KM, are preferably within 3, 2, or 1 order of magnitude of the values ​​exhibited by the reference molecule in relation to a specific substrate. Similarly, the term "variant" of a nucleic acid encompasses nucleic acids whose complementary strand hybridizes, preferably under rigorous conditions, with the reference or wild-type nucleic acid. In one example, the variant of SEQ ID NO: 4 may exhibit 60% sequence identity with SEQ ID NO: 4.

[019] In one example, the E2 enzyme can present the polypeptide sequence SEQ ID NO: 2 or a polypeptide sequence in which up to 25%, particularly up to 20%, more particularly up to 15%, and especially up to 10, 9, 8, 7, 6, 5, 4, 3, 2, 1% of the amino acid radicals are modified compared to the reference sequence SEQ ID NO: 2 by deletion, insertion, substitution or a combination thereof, and which still exhibits at least 10%, particularly 50%, more particularly 80%, and even more particularly more than 90% of the enzymatic activity of the enzyme possessing the reference sequence SEQ ID NO: 2, and the enzymatic activity of enzyme E2 is understood as the ability, in particular, to convert 3-hydroxy-alkanoyl-3-hydroxy-alkanoyl-CoA / ACP or 3-(3-hydroxyalkanoyloxy)alkanoic acid (HAA) into β-D-glucopyranosyl-3-hydroxyalkanoyl-3-hydroxyalkanoate. NDP-glucose may be present in this conversion.

[020] In another example, the E2 enzyme can present the polypeptide sequence SEQ ID NO: 8 or a polypeptide sequence in which up to 25%, particularly up to 20%, more particularly up to 15%, and especially up to 10, 9, 8, 7, 6, 5, 4, 3, 2, 1% of the amino acid radicals are modified compared to the reference sequence SEQ ID NO: 8 by deletion, insertion, substitution or a combination thereof, and which still exhibits at least 10%, particularly 50%, more particularly 80%, and even more particularly more than 90% of the enzymatic activity of the enzyme possessing the reference sequence SEQ ID NO: 8, with Petition 870250101536, dated 06 / 11 / 2025, pp. 128 / 174 10 / 49 The enzymatic activity of the E2 enzyme is understood as the ability, in particular, to convert 3-hydroxy-alkanoyl-3-hydroxy-alkanoyl-CoA / ACP or 3-(3-hydroxyalkaneoyloxy)alkanoic acid (HAA) into eD-glucopyranosyl-3-hydroxy-alkanoyl-3-hydroxyalkanoate. NDP-glucose may be present in this conversion.

[021] In one example, the E2 enzyme can present the polypeptide sequence SEQ ID NO: 12 or a polypeptide sequence in which up to 25%, particularly up to 20%, more particularly up to 15%, and especially up to 10, 9, 8, 7, 6, 5, 4, 3, 2, 1% of the amino acid radicals are modified compared to the reference sequence SEQ ID NO: 12 by deletion, insertion, substitution or a combination thereof, and which still exhibits at least 10%, particularly 50%, more particularly 80%, and even more particularly more than 90% of the enzymatic activity of the enzyme possessing the reference sequence SEQ ID NO: 12, and the enzymatic activity of enzyme E2 is understood as the ability, in particular, to convert 3-hydroxy-alkanoyl-3-hydroxy-alkanoyl-CoA / ACP or 3-(3-hydroxy-alkanoyloxy)alkanoic acid (HAA) into eD-glucopyranosyl-3-hydroxyalkanoyl-3-hydroxyalkanoate. NDP-glucose may be present in this conversion.

[022] In particular, the use of SEQ ID NO: 2, SEQ ID NO: 6 or SEQ ID NO: 12 (i.e., from Pantoea spec.) as E2, compared with the use of E2 from other organisms, for example, Serratia rubidaea, may lead to the production of higher amounts of rubiwettins.

[023] In one example, the cell according to any aspect of the present invention is genetically modified to increase heterologous expression relative to the wild-type cell of: - Enzyme E1, a 3-(3-hydroxyalkaneyloxy)alkanoic acid (HAA) synthase, comprising SEQ ID NO: 1, or a variant thereof, and the variant has 60% sequence identity with SEQ ID NO: 1. - Enzyme E2, a glycosyltransferase (EC 2.4) comprising SEQ ID NO: 2, or a variant thereof, and the variant exhibits 60% sequence identity with SEQ ID NO: 2. Petition 870250101536, dated 06 / 11 / 2025, pp. 129 / 174 11 / 49

[024] In another example, the cell, according to any aspect of the present invention, is genetically modified to increase heterologous expression relative to the wild-type cell of: - Enzyme E1, a 3-(3-hydroxy-alkanoyloxy)alkanoic acid (HAA) synthase, comprising SEQ ID NO: 7, or a variant thereof, and the variant has 60% sequence identity with SEQ ID NO: 7. - Enzyme E2, a glycosyltransferase (EC 2.4) comprising SEQ ID NO: 8, or a variant thereof, and the variant exhibits 60% sequence identity with SEQ ID NO: 8.

[025] In a further example, the cell, according to any aspect of the present invention, is genetically modified to increase heterologous expression relative to the wild-type cell of: - Enzyme E1, a 3-(3-hydroxyalkaneyloxy)alkanoic acid (HAA) synthase, comprising SEQ ID NO: 11, or a variant thereof, wherein the variant exhibits 60% sequence identity with SEQ ID NO: 11; and - Enzyme E2, a glycosyltransferase (EC 2.4) comprising SEQ ID NO: 12, or a variant thereof, and the variant exhibits 60% sequence identity with SEQ ID NO: 12.

[026] In one example, the cell, according to any aspect of the present invention, is genetically modified to increase heterologous expression relative to the wild-type cell of: - Enzyme E1, a 3-(3-hydroxyalkaneyloxy)alkanoic acid (HAA) synthase, comprising SEQ ID NO: 15, or a variant thereof, wherein the variant exhibits 60% sequence identity with SEQ ID NO: 15; and - Enzyme E2, a glycosyltransferase (EC 2.4) comprising SEQ ID NO: 2, or a variant thereof, and the variant exhibits 60% sequence identity with SEQ ID NO: 2.

[027] In another example, the cell according to any aspect of the present invention is genetically modified to increase heterologous expression in Petition 870250101536, dated 06 / 11 / 2025, pp. 130 / 174 12 / 49 relative to the wild-type cell: - Enzyme E1, a 3-(3-hydroxyalkaneyloxy)alkanoic acid (HAA) synthase, comprising SEQ ID NO: 15, or a variant thereof, wherein the variant exhibits 60% sequence identity with SEQ ID NO: 15; and - Enzyme E2, a glycosyltransferase (EC 2.4) comprising SEQ ID NO: 8, or a variant thereof, and the variant exhibits 60% sequence identity with SEQ ID NO: 8.

[028] In another example, the cell, according to any aspect of the present invention, is genetically modified to increase heterologous expression relative to the wild-type cell of: - Enzyme E1, a 3-(3-hydroxyalkaneyloxy)alkanoic acid (HAA) synthase, comprising SEQ ID NO: 15, or a variant thereof, wherein the variant exhibits 60% sequence identity with SEQ ID NO: 15; and - Enzyme E2, a glycosyltransferase (EC 2.4) comprising SEQ ID NO: 12, or a variant thereof, and the variant exhibits 60% sequence identity with SEQ ID NO: 12.

[029] The lipid of general formula II may also be called a glycolipid. The length of groups R1 and R2 can vary. In particular, R1 and R2 can be selected independently from the group consisting of saturated and unsaturated alkyls. More specifically, R1 and / or R2 can be a saturated or unsaturated alkyl group with 5 to 13 carbon atoms. Even more specifically, R1 and R2 can be a saturated or monounsaturated alkyl group with 5 to 13 carbon atoms. The alkyl group R1 and R2 can comprise 5 to 13 carbon atoms, 7 to 13 carbon atoms, 9 to 13 carbon atoms, 5 to 11 carbon atoms, 5 to 9 carbon atoms, and the like. In examples where the alkyl group R1 and / or R2 is a saturated alkyl group, the alkyl group may comprise 5, 6, 7, 8, 9, 10, 11, 12, or 13 carbon atoms. In examples where the alkyl group R1 and / or R2 is an unsaturated alkyl group, the alkyl group may be a monounsaturated alkyl comprising 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, or 12:1. Petition 870250101536, dated 06 / 11 / 2025, pp. 131 / 174 13 / 49 or 13:1 carbon atoms. More specifically, the alkyl group R1 and / or R2 is a saturated alkyl group with 5 to 13 carbon atoms. The cell, according to any aspect of the present invention, may be able to produce a mixture of rubiwettins with varying R1 and R2 groups. In one example, the lipid of general formula II produced according to any aspect of the present invention may be a rubiwettin RG1 (CAS No. 129039-46-9). Rubiwettin RG1 may also be referred to as a glycolipid called e-D-Glucopyranosyl-3-(3'-hydroxytetradecanoyloxy)decanoate or e-Glucopyranosyl-3-(3'-hydroxytetradecanoyloxy)decanoate.

[030] The cell, according to any aspect of the present invention, can produce an additional lipid with general formula I from a carbon substrate. General Formula I with R1 and R2, independently of each other, being identical or different alkyl groups with 5 to 13 carbon atoms. In particular, the alkyl group may be saturated or unsaturated. More specifically, the alkyl group of R1 and / or R2 may be a saturated alkyl radical. Even more specifically, R1 and / or R2 may be selected from the group consisting of pentyl, heptyl, nonyl, undecyl, tridecyl and (CH2)n-CH3 with n = 4-12.

[031] The lipid of general formula I may have R1 and R2 groups of varying lengths. In particular, R1 and R2 may be selected independently from the group consisting of saturated and unsaturated alkyls. More specifically, R1 and / or R2 may be a saturated or unsaturated alkyl group with 5 to 13 carbon atoms. Even more specifically, R1 and R2 may be a saturated or monounsaturated alkyl group with 5 to 13 carbon atoms. The alkyl group R1 and R2 may comprise 5 to 13 carbon atoms, 7 to 13 carbon atoms, 9 to 13 carbon atoms, 5 to 11 carbon atoms, 5 to 9 carbon atoms, and the like. In examples where the group Petition 870250101536, dated 06 / 11 / 2025, pp. 132 / 174 14 / 49 alkyl R1 and / or R2 is an unsaturated alkyl group, the alkyl group may be a monounsaturated alkyl comprising 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1 or 13:1 carbon atoms. In instances where the alkyl group R1 and / or R2 is a saturated alkyl group, the alkyl group may comprise 5, 6, 7, 8, 9, 10, 11, 12 or 13 carbon atoms. The cell, according to any aspect of the present invention, may be able to produce a mixture of lipids with varying R1 and R2 groups. In particular, the lipid with formula I may also be called rubiwettin R1 (CAS No. 129039-45-8). In particular, the lipid is a mixture of 3-(3'-hydroxytetradecanoyloxy)tetradecanoate, 3-(3'-hydroxydecanoyloxy)decanoate, 3-(3'-hydroxyhexadecenoyloxy)hexadecenoate, 3-(3'-hydroxytetradecanoyloxy)decanoate, 3(3'-hydroxyhexadecenoyloxy)decanoate, 3-(3'-hydroxyhexadecenoyloxy)tetradecanoate and minor molecular isomers.

[032] Surprisingly, it has been shown that recombinant cells, according to any aspect of the present invention, with increased expression of E2 and / or E1 are capable of producing increased amounts of lipids with formulas II and / or I compared with the wild-type cell. The cells, according to any aspect of the present invention, can therefore allow a highly selective production of RG1 rubiwettins with reduced production of undesirable intermediates such as β-hydroxylated fatty acid dimers.

[033] In particular, the use of SEQ-IDs 1, 7 and 11 from Pantoea sp. as E1, instead of the E1 sequences from Pseudomonas aeruginosa, leads to a change in rubiwettin species from C10:0-C12:1 and C10:0-C12:0 to C8:0-C10:0. Rubiwettin species with shorter 3-hydroxylated fatty acid chains may exhibit different application profiles than rubiwettin species with longer 3-hydroxylated fatty acid chains.

[034] The expression “increased heterologous expression of an enzyme”, as used in this document, should be understood as an increase in intracellular activity. Basically, an increase in enzymatic activity can be achieved by increasing the number of copies of the genetic sequence or genetic sequences. Petition 870250101536, dated 06 / 11 / 2025, pages 133 / 174 15 / 49 that encode the enzyme using a strong promoter or employing a gene or allele that encodes a corresponding enzyme with increased activity and, optionally, combining these measures. Genetically modified cells used in the method according to the invention are, for example, produced by transformation, transduction, conjugation or a combination of these methods with a vector containing the desired gene, an allele of that gene or parts thereof, and a vector that enables gene expression. In particular, heterologous expression is achieved by integrating the gene or alleles into the cell chromosome or an extrachromosomally replicating vector. In particular, an increase in the activity of an enzyme relative to the wild-type cell can be 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100% higher than that of the wild-type cell.

[035] An expert would be able to use any method known in the art to genetically modify a cell. Whether a nucleic acid molecule, polypeptide, more specifically an enzyme used in accordance with any aspect of the present invention, is recombinant or not, this does not necessarily have implications for the level of its expression. However, in one example, one or more recombinant nucleic acid molecules, polypeptides or enzymes used in accordance with any aspect of the present invention may be overexpressed. The term “overexpressed”, as used herein, means that the respective encoded or expressed polypeptide is expressed at a higher level or with higher activity than would normally be found in the cell under identical conditions in the absence of genetic modifications made to increase expression, for example, in the respective wild-type cell.The specialist is familiar with various ways to promote overexpression. For example, the nucleic acid molecule to be overexpressed, or the one encoding the polypeptide or enzyme to be overexpressed, can be placed under the control of a strong, inducible promoter, such as the lac promoter. The state of the art describes standard plasmids that can be used for this purpose, for example, the pET vector system. Petition 870250101536, dated 06 / 11 / 2025, pages 134 / 174 16 / 49 exemplified by pET-3a (commercially available from Novagen). Whether or not a nucleic acid or polypeptide is overexpressed can be determined by quantitative PCR reaction, in the case of a nucleic acid molecule, or by SDS polyacrylamide gel electrophoresis, Western blotting, or comparative activity assays, in the case of a polypeptide. Genetic modifications can be directed towards transcriptional, translational, and / or post-translational modifications that result in a change in enzyme activity and / or selectivity under selected and / or identified culture conditions. Thus, in several examples of the present invention, to function more efficiently, a microorganism may comprise one or more gene deletions.Gene deletions can be performed by gene deletion approaches by mutation and / or from a mutant lineage with reduced or absent expression of one or more of these enzymes, and / or by other methods known to qualified professionals in the field.

[036] Document DE-A-100 31 999 presents an overview of the possibilities of increasing enzymatic activity in cells, exemplified by pyruvate carboxylase, and is incorporated herein by reference, and whose content, with regard to the possibilities of increasing enzymatic activity in cells, constitutes part of the disclosure of the present invention.

[037] The expression of the enzymes or genes mentioned above and all those subsequently cited is detectable with the aid of one-dimensional and two-dimensional protein gel separation, followed by optical identification of the protein concentration in the gel using appropriate analytical software. If the increase in enzyme activity is based solely on the increase in the expression of the corresponding gene, the quantification of this increase can be easily determined by comparing the one-dimensional or two-dimensional protein separations between the wild-type cell and the genetically modified cell. A common method for preparing protein gels in the case of coryneform bacteria and for identifying the proteins is the procedure described by Hermann et al. (Electrophoresis, 22: 1712.23 (2001)). The protein concentration also Petition 870250101536, dated 06 / 11 / 2025, pages 135 / 174 17 / 49 can be analyzed by Western blot hybridization using a specific antibody for the protein to be detected (Sambrook et al., Molecular Cloning: a laboratory manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (Sambrook et al., Molecular Cloning: a laboratory manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA, 1989) and subsequent optical analysis using appropriate software for concentration determination (Lohaus and Meyer (1989), Biospektrum, 5: 32-39; Lottspeich (1999), Angewandte Chemie 111: 2630-2647). The activity of DNA-binding proteins can be measured by means of DNA band displacement assays (also called gel retardation) (Wilson et al.). (2001) Journal of Bacteriology, 183: 2151-2155). The action of DNA-binding proteins on the expression of other genes can be detected by several well-described reporter gene assay methods (Sambrook et al., Molecular Cloning: a laboratory manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY USA, 1989). Intracellular enzymatic activities can be determined according to several methods described (Donahue et al.). (2000) Journal of Bacteriology 182 (19): 5624-5627; Ray et al. (2000) Journal of Bacteriology 182 (8): 2277-2284; Freedberg et al. (1973), Journal of Bacteriology, 115 (3): 816-823). If practical methods for determining the activity of a given enzyme are not indicated in the following modalities, the determination of the increase in enzymatic activity, as well as the decrease in this activity, preferably occurs through the methods described by Hermann et al., Electrophoresis, 22: 1712-1723 (2001); Lohaus et al., Biospektrum 5: 32-39 (1998); Lottspeich, Angewandte Chemie 111: 2630-2647 (1999); Wilson et al., Journal of Bacteriology, 183: 2151-2155 (2001).

[038] If the increase in enzymatic activity is obtained by mutation of the endogenous gene, such mutations can be produced randomly by conventional methods, such as, for example, UV irradiation or mutagenic chemical agents, or selectively by means of genetic engineering methods, such as deletions, insertions and / or nucleotide exchanges. The modified cells are obtained Petition 870250101536, dated 06 / 11 / 2025, pages 136 / 174 18 / 49 due to these mutations. Particularly preferred enzyme mutants are, in particular, those enzymes that are no longer inhibited by feedback, product or substrate, or that are inhibited to a reduced degree, at least compared to the wild-type enzyme.

[039] If increased enzymatic activity is achieved by increasing the synthesis of an enzyme, the number of copies of the corresponding genes is increased, or the promoter and regulatory region, or the ribosome binding site, located upstream of the structural gene, is mutated. Expression cassettes, which are incorporated upstream of the structural gene, act in the same way. It is also possible, through inducible promoters, to increase expression at any desired time. Furthermore, “enhancers” can also be assigned to the enzyme gene as regulatory sequences, which similarly promote increased gene expression through enhanced interaction between RNA polymerase and DNA. As a result of measures to extend mRNA lifetime, expression is also enhanced. In addition, by preventing the degradation of the enzymatic protein, enzyme activity is also increased.Genes or gene constructs are present here, either in plasmids with different copy numbers, or integrated and amplified in the chromosome. Alternatively, overexpression of the genes in question can also be obtained through modification of the medium composition and crop management. The specialist in the area can find guidance for this, among other sources, in Martin et al. (Bio / Technology 5, 137-146 (1987)), in Guerrero et al. (Genes 138, 35-41 (1994)), Tsuchiya and Morinaga (Bio / Technology 6, 428-430 (1988)), in Eikmanns et al. (Genes 102, 93-98 (1991)), in EP-A-0 472 869, in US 4,601,893, in Schwarzer and Pühler (Bio / Technology 9, 84-87 (1991)), in Reinscheid et al. (Applied and Environmental Microbiology 60, 126132 (1994)), in LaBarre et al. (Journal of Bacteriology 175, 1001-1007 (1993)), in patent WO-A-96 / 15246, in Malumbres et al.(Genes 134, 15-24 (1993)), in patent JP-A-10-229891, in Jensen and Hammer (Biotechnology and Bioengineering 58, 191195 (1998)) and in well-known textbooks on genetics and molecular biology. The measurements. Petition 870250101536, dated 06 / 11 / 2025, pages 137 / 174 19 / 49 described above also lead, just like mutations, to the production of genetically modified cells.

[040] Episomal plasmids, for example, are used to increase the expression of the respective genes. Suitable plasmids or vectors are, in principle, all the modalities available for this purpose to the specialist in the field. Such plasmids and vectors can be obtained, for example, from the catalogs of the companies Novagen, Promega, New England Biolabs, Clontech or Gibco BRL. Additional preferred plasmids and vectors can be found in: Glover, DM (1985) DNA Cloning: A Practical Approach, Vol. I-III, IRL Press Ltd., Oxford; Rodriguez, RL and Denhardt, D. T (eds) (1988) Vectors: A Survey of Molecular Cloning Vectors and Their Uses, 179-204, Butterworth, Stoneham; Goeddel, DV (1990) Systems for Heterologous Gene Expression, Methods Enzymol. 185, 3-7; Sambrook, J.; Fritsch, E.F. and Maniatis, T. (1989), Molecular cloning: a laboratory manual, 2nd ed., Cold Spring Harbor Laboratory Press, New York.

[041] The plasmid vector, which contains the gene to be amplified, is then introduced into the desired strain by conjugation or transformation. The conjugation method is described, for example, in Schäfer et al., Applied and Environmental Microbiology 60: 756-759 (1994). Transformation methods are described, for example, in Thierbach et al., Applied Microbiology and Biotechnology 29: 356-362 (1988), Dunican and Shivnan, Bio / Technology 7: 1067-1070 (1989) and Tauch et al., FEMS Microbiology Letters 123: 343-347 (1994). After homologous recombination through a “cross-over” event, the resulting strain contains at least two copies of the gene in question.

[042] According to any aspect of the present invention, the cell can be genetically modified so that, within a defined time interval, within 2 hours, in particular within 8 hours or 24 hours, it produces at least twice, especially at least 10 times, at least 100 times, at least 1000 times or at least 10000 times more lipids of General Formula I or II than the wild-type cell. The increase in product formation can be determined, Petition 870250101536, dated 06 / 11 / 2025, pp. 138 / 174 20 / 49 for example, by separately cultivating the cell according to any aspect of the present invention and the wild-type cell under the same conditions (same cell density, same nutrient medium, same culture conditions) for a specified time interval in a suitable nutrient medium and then determining the amount of the target product (lipid with general formula II or I) present in the nutrient medium.

[043] Alterations in the amino acid residues of a given polypeptide sequence, which do not result in significant changes in the properties and function of said polypeptide, are known to the specialist in the field. Thus, for example, “conserved amino acids” can be exchanged among themselves; examples of suitable amino acid substitutions include: Ala for Ser; Arg for Lys; Asn for Gln or His; Asp for Glu; Cys for Ser; Gln for Asn; Glu for Asp; Gly for Pro; His for Asn or Gln; Ile for Leu or Val; You leu for Met or Val; Lys for Arg or Gln or Glu; Met for Leu or Ile; Phe for Met or Leu or Tyr; Ser for Thr; Thr for Ser; Trp for Tyr; Tyr for Trp or Phe; Val for Ile or Leu. It is also well known that alterations, particularly at the N-terminal or C-terminal end of a polypeptide, in the form of, for example, amino acid insertions or deletions, often do not exert a significant influence on the function of the polypeptide.

[044] The desired enzyme can be isolated by disrupting the cells containing the desired activity in a manner known to those skilled in the art, for example, with the aid of a ball mill, a French press or an ultrasonic disintegrator, and subsequently separating the cells, cell debris and disruption aids, such as glass beads, by centrifugation for 10 minutes at 13,000 rpm and 4 °C. Using the resulting cell-free crude extract, enzymatic assays can then be performed with subsequent detection of the products by LC-ESI-MS. Alternatively, the enzyme can be enriched in a manner known to those skilled in the art by chromatographic methods (such as nickel nitrilotriacetic acid affinity chromatography, streptavidin affinity chromatography, gel filtration chromatography or chromatography of Petition 870250101536, dated 06 / 11 / 2025, pages 139 / 174 21 / 49 ion exchange), or further purified until homogeneous.

[045] In one example, the method used to determine enzyme activity E2 first involves disrupting cells containing this activity (i.e., cells according to any aspect of the present invention) in a manner known to those skilled in the art, for example, with the aid of a ball mill, a French press, or an ultrasonic disintegrator, followed by separating the cells, cell debris, and disrupting agents, such as glass beads, by centrifugation for 10 minutes at 16,100 g and 4°C. Using the resulting cell-free crude extract, enzymatic assays can be performed with subsequent detection of the products by LC-ESI-MS. Alternatively, the enzyme can be enriched in a manner known to those skilled in the art by chromatographic methods (such as nickel / nitrilotriacetic acid affinity chromatography, streptavidin affinity chromatography, gel filtration chromatography, or ion-exchange chromatography), or further purified to homogeneity.This sample can then be used to measure the activity of the E2 enzyme. In particular, the activity of the E2 enzyme can be determined using a standard assay that may consist of 185 µl of 10 mM Tris-HCl (pH 7.5), 10 µl of 1 mM NDP-glucose, and 50 µl of crude protein extract (approximately 1 mg of total protein) or purified protein in solution (5 pg of purified protein). The reaction can be initiated by adding 10 µl of 1 mM ethanolic solution of 3-hydroxytetradecanoyl-3-hydroxydecanoic acid or 3-hydroxyhexadecanoyl-3-hydroxydecanoic acid and incubating for 1 hour at 30 °C with stirring (600 rpm). Subsequently, the reaction can be treated with 1 ml of acetone. Undissolved constituents can be sedimented by centrifugation (16,100 g, 5 minutes, room temperature), and the sample can be analyzed by LCESI-MS. Product identification can then be performed by analyzing the corresponding mass traces and MS2 spectra.This method can be used to measure the activity of the E2 enzyme.

[046] In another example, the method used to determine the activity of the E1 enzyme first involves disrupting cells that contain this activity. Petition 870250101536, dated 06 / 11 / 2025, pages 140 / 174 22 / 49 (i.e., the cells according to any aspect of the present invention), in a manner known to those skilled in the art, followed by separation of the cells, cell debris and disrupting agents, such as glass beads, by centrifugation for 10 minutes at 16,100 g and 4°C. Using the resulting cell-free crude extract, enzymatic assays can be performed with subsequent detection of the products by LC-ESI-MS. Alternatively, the enzyme can be enriched in a manner known to those skilled in the art by chromatographic methods (such as nickel / nitrilotriacetic acid affinity chromatography, streptavidin affinity chromatography, gel filtration chromatography or ion exchange chromatography), or further purified to homogeneity. This sample can then be used to measure the activity of the E1 enzyme. In particular, the activity of the E1 enzyme can be determined using a standard assay that may contain 100 μM of E. aCP.coli, 1 mM β-mercaptoethanol, 200 μΜ malonyl coenzyme A, 40 μΜ octanoyl coenzyme A and 40 μΜ dodecanoyl coenzyme A or 40 μΜ octanoyl coenzyme A and 40 μΜ tetradecanoyl coenzyme A, 100 μΜ NADPH, 2 μg of E. coli FabD, 2 μg of Mycobacterium tuberculosis FabH, 1 μg of E. coli FabG, 0.1 Μ sodium phosphate buffer (pH 7.0) and 5 μg of the E1 enzyme in a final volume of 120 μl. ACP, β-mercaptoethanol, and sodium phosphate buffer can be pre-incubated for 30 minutes at 37 °C to completely reduce ACP. The reaction can be initiated by adding enzyme E1. Reactions can be stopped with 2 ml of water acidified with HCl to pH 2.0, and subsequently extracted twice with 2 ml of chloroform / methanol (2:1, v / v). Phase separation can be performed by centrifugation (16,100 g, 5 minutes, room temperature). The lower organic phase can be removed, completely evaporated in a vacuum centrifuge, and the sediment can be resuspended in 50 μl of methanol.Undissolved constituents can be sedimented by centrifugation (16,100 g, 5 minutes, room temperature), and the sample can be analyzed by LC-ESI-MS. Product identification can be performed by analyzing the corresponding mass traces and MS2 spectra. Petition 870250101536, dated 06 / 11 / 2025, pages 141 / 174 23 / 49

[047] The enzyme used in accordance with any aspect of the present invention may be recombinant. The term “recombinant,” as used in this document, refers to a molecule or something encoded by such a molecule, particularly a polypeptide or nucleic acid that, as such, does not occur naturally but is the result of genetic engineering, or refers to a cell comprising a recombinant molecule. For example, a nucleic acid molecule is considered recombinant if it comprises a promoter functionally linked to a sequence encoding a catalytically active polypeptide, and the promoter has been modified so that the catalytically active polypeptide is overexpressed relative to the level of the polypeptide in the corresponding wild-type cell containing the original unmodified nucleic acid molecule.

[048] The cell used according to any aspect of the present invention may also be a non-pathogenic cell. A non-pathogenic cell refers to a cell that does not cause disease, damage or death to another organism. The cells according to any aspect of the present invention may be any non-pathogenic prokaryote or eukaryote. These may be mammalian cells (such as, for example, human cells), plant cells or microorganisms such as yeasts, fungi or bacteria, microorganisms, in particular bacteria and yeasts, being preferred.

[049] Suitable bacteria, yeasts or fungi are, in particular, those deposited at Deutsche Sammlung von Mikroorganismen und Zellkulturen (German Collection of Microorganisms and Cell Cultures) GmbH (DSMZ), in Brunswick, Germany, as bacterial, yeast or fungal strains. Suitable bacteria according to the invention belong to the genera listed in: - http: / / www.dsmz.de / species / bacteria.htm, Suitable yeasts according to the invention belong to the genera listed in: - http: / / www.dsmz.de / species / yeasts.htm and the suitable fungi according to the invention are those listed at: Petition 870250101536, dated 06 / 11 / 2025, pages 142 / 174 24 / 49 - http: / / www.dsmz.de / species / fungi.htm.

[050] In particular, cells can be selected from the genera Aspergillus, Corynebacterium, Brevibacterium, Bacillus, Acinetobacter, Alcaligenes, Lactobacillus, Paracoccus, Lactococcus, Candida, Pichia, Hansenula, Kluyveromyces, Saccharomyces, Escherichia, Zymomonas, Yarrowia, Methylobacterium, Ralstonia, Pseudomonas, Rhodospirillum, Rhodobacter, Burkholderia, Clostridium e Cupriavidus. More specifically, the cells can be selected from the group consisting of Aspergillus nidulans, Aspergillus niger, Alcaligenes latus, Bacillus megaterium, Bacillus subtilis, Brevibacterium flavum, Brevibacterium lactofermentum, Burkholderia andropogonis, B. brasilensis, B. caledonica, B. caribensis, B. caryophylli, B. fungorum, B. gladioli, B. glathei, B. glumae, B. graminis, B. hospita, B. kururiensis, B. phenazinium, B. phymatum, B. phytofirmans, B. plantarii, B. sacchari, B. singaporensis, B. sordidicola, B. terricola, B. tropica, B. tuberum, B. ubonensis, B. unamae, B. xenovorans, B. anthina, B. pyrrocinia, B.thailandensis, Candida blankii, Candida rugosa, Corynebacterium glutamicum, Corynebacterium efficiens, Escherichia coli, Hansenula polymorpha, Kluveromyces lactis, Methylobacterium extorquens, Paracoccus versutus, Pseudomonas argentinensis, P. borbori, P. citronellolis, P. flavescens, P. mendocina, P. nitroreducens, P. oleovorans, P. pseudoalcaligenes, P. resinovorans, P. straminea, P. aurantiaca, P. aureofaciens, P. chlororaphis, P. fragi, P. lundensis, P. taetrolens, P. antarctica, P. azotoformans, 'P. blatchfordae', P. brassicacearum, P. brenneri, P. cedrina, P. corrugata, P. fluorescens, P. gessardii, P. libanensis, P. mandelii, P. marginalis, P. mediterranea, P. meridiana, P. migulae, P. mucidolens, P. orientalis, P. panacis, P. proteolytica, P. rhodesiae, P. synxantha, P. thivervalensis, P. tolaasii, P. veronii, P. denitrificans, P. pertucinogena, P. cremoricolorata, P. fulva, P. monteilii, P. mosselii, P. parafulva, P. putida, P. balearica, P. stutzeri, P. amygdali, P.avellanae, P. caricapapayae, P. cichorii, P. coronafaciens, P. ficuserectae, 'P. helianthi', P. meliae, P. savastanoi, P. syringae, P. tomato, P. viridiflava, P. abietaniphila, P. acidophila, P. agarici, P. alcaliphila, P. alkanolytica, P. amyloderamosa, P. asplenii, P. azotifigens, P. cannabina, P. Petition 870250101536, dated 06 / 11 / 2025, p. 143 / 174 25 / 49 coenobios, P. congelans, P. costantinii, P. cruciviae, P. delhiensis, P. excibis, P. extremorientalis, P. frederiksbergensis, P. fuscovaginae, P. gelidicola, P. grimontii, P. indica, P. jessenii, P. jinjuensis, P. kilonensis, P. knackmussii, P. koreensis, P. lini, P. lutea, P. moraviensis, P. otitidis, P. pachastrellae, P. palleroniana, P. papaveris, P. peli, P. perolens, P. poae, P. pohangensis, P. psychrophila, P. psychrotolerans, P. rathonis, P. reptilivora, P. resiniphila, P. rhizosphaerae, P. rubescens, P. salomonii, P. segitis, P. septica, P. simiae, P. suis, P. thermotolerans, P. aeruginosa, P. tremae, P. trivialis, P. turbinellae, P. tuticorinensis, P. umsongensis, P. vancouverensis, P. vranovensis, P. xanthomarina, Ralstonia eutropha, Rhodospirillum rubrum, Rhodobacter sphaeroides, Saccharomyces cerevisiae, Yarrowia lipolytica from Zymomonas mobile. More specifically, a cell pode ser uma bacterial cell selected from partir do grupo constituto por Acinetobacter sp., Bacillus sp., Brevibacterium sp., Burkholderia sp., Chlorella sp., Clostridium sp., Corynebacterium sp., cyanobacteria, Escherichia sp., Pseudomonas sp., Klebsiella sp., Salmonella sp., Rhizobium sp., Saccharomyces sp., Pichia sp. and Nostoc sp. Even more specifically, the cell can be selected from the group consisting of Bacillus subtilis, Burkholderia thailandensis, Corynebacterium glutamicum, E. coli, Klebsiella oxytoca, Pseudomonas fluorescens, Pseudomonas putida, Pseudomonas stutzeri, Rhizobium meliloti, Saccharomyces cerevisiae and Pichia pastoris.

[051] In one example, the cell according to any aspect of the present invention may be a genetically modified cell to increase the expression of: - enzyme E2, which comprises the SEQ ID NO: 2, and - enzyme E1, which includes SEQ ID NO: 1 and its variants.

[052] In another example, the cell, according to any aspect of the present invention, may be a genetically modified cell to increase the expression of: - enzyme E1, comprising SEQ ID NO: 1 or a variant thereof, and enzyme E2, comprising SEQ ID NO: [number] 8 or a variant thereof, Petition 870250101536, dated 06 / 11 / 2025, pp. 144 / 174 26 / 49 or - enzyme E1, comprising SEQ ID NO: 1 or a variant thereof, and enzyme E2, comprising SEQ ID NO: 12 or a variant thereof, or - enzyme E1, comprising SEQ ID NO: 7 or a variant thereof, and enzyme E2, comprising SEQ ID NO: 2 or a variant thereof, or - enzyme E1, comprising SEQ ID NO: 7 or a variant thereof, and enzyme E2, comprising SEQ ID NO: 8 or a variant thereof, or - enzyme E1, comprising SEQ ID NO: 7 or a variant thereof, and enzyme E2, comprising SEQ ID NO: 12 or a variant thereof, or - enzyme E1, comprising SEQ ID NO: 11 or a variant thereof, and enzyme E2, comprising SEQ ID NO: 2 or a variant thereof, or - enzyme E1, comprising SEQ ID NO: 11 or a variant thereof, and enzyme E2, comprising SEQ ID NO: 8 or a variant thereof, or - enzyme E1, comprising SEQ ID NO: 11 or a variant thereof, and enzyme E2, comprising SEQ ID NO: 12 or a variant thereof, or - enzyme E1, comprising SEQ ID NO: 15 or a variant thereof, and enzyme E2, comprising SEQ ID NO: 2 or a variant thereof, - enzyme E1, comprising SEQ ID NO: 15 or a variant thereof, and enzyme E2, comprising SEQ ID NO: 8 or a variant thereof, or - enzyme E1, comprising SEQ ID NO: 15 or a variant thereof, and enzyme E2, comprising SEQ ID NO: 12 or a variant thereof.

[053] Cells, according to any aspect of the present invention, can be used to produce a lipid according to general formula I and / or II from a carbon substrate: R1 0R2 General Formula I Petition 870250101536, dated 06 / 11 / 2025, pp. 145 / 174 27 / 49 General Formula II wherein R1 and R2, independently of each other, in General Formula I or II, are identical or different alkyl groups with 5 to 13 carbon atoms. In particular, the alkyl group may be saturated or unsaturated. More specifically, the alkyl group of R1 and / or R2 may be a saturated alkyl radical. Even more specifically, R1 and / or R2 may be selected from the group consisting of pentyl, heptyl, nonyl, undecyl, tridecyl and (CH2)n-CH3, with n = 4-12.

[054] The lipids formed may be a combination of lipids with the general formula I and II, with varying R groups, which may be produced during a single reaction.

[055] Genetically modified cells, according to the invention, can be placed in contact with the nutrient medium continuously or discontinuously, in the batch process (batch culture), in the fed-batch process (fed-batch process) or in the repeated fed-batch process (repetitive fed-batch process), for the purpose of producing the products mentioned above and thus cultivated. A semi-continuous process is also conceivable, as described in GB-A-1009370. A summary of known cultivation methods is described in Chmiel's textbook (“Bioprozesstechnik 1”). “Einführung in die Bioverfahrenstechnik” [Bioprocess Technology 1]. [Introduction to Bioprocess Technique] (Gustav Fischer Verlag, Stuttgart, 1991) or in Storhas' textbook (“Bioreaktoren und periphere Einrichtungen” [Bioreators and Peripheral Equipment], Vieweg Verlag, Brunswick / Wiesbaden, 1994).

[056] The culture medium to be used must adequately meet the requirements of the respective strains. Descriptions of culture media of different Petition 870250101536, dated 06 / 11 / 2025, pages 146 / 174 28 / 49 yeast strains are contained, for example, in “Nonconventional Yeast in Biotechnology” (Ed. Klaus Wolf, Springer-Verlag Berlin, 1996).

[057] The carbon source used as a substrate, according to any aspect of the present invention, may be selected from the group consisting of carbohydrates such as, for example, glucose, sucrose, arabinose, xylose, lactose, fructose, maltose, molasses, starch, cellulose and hemicellulose; vegetable and animal oils and fats such as, for example, soybean oil, safflower oil, peanut oil, hemp seed oil, jatropha oil, coconut fat, gourd oil, linseed oil, corn oil, poppy seed oil, evening primrose oil, olive oil, palm kernel oil, palm oil, rapeseed oil, sesame oil, sunflower oil, grape seed oil, walnut oil, wheat germ oil and coconut oil;Fatty acids such as, for example, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, arachidonic acid, behenic acid, oleic acid, linoleic acid, linolenic acid, gamma-linolenic acid and their methyl or ethyl esters, as well as mixtures of fatty acids; mono-, di- and triglycerides containing the aforementioned fatty acids; alcohols such as, for example, glycerol, ethanol and methanol; hydrocarbons such as methane, ethane, propane or butane; carbon-containing gases and gaseous mixtures such as CO, CO2, synthesis gas or combustion gas; amino acids such as L-glutamate or L-valine;or organic acids such as, for example, acetic acid. These substances can be used individually or as a mixture. The use of carbohydrates, in particular monosaccharides, oligosaccharides or polysaccharides, as a carbon source, as described in US patents 6,014,94 and 6,136,576, as well as hydrocarbons, especially alkanes, alkenes and alkynes. In particular, the carbon source can be selected from the group consisting of glucose, dextrose, sucrose, mannose, galactose, polysaccharides such as cellulose or hemicelluloses, vegetable oils, animal fats, fatty acids, fatty acid esters, carbonaceous gases, alkanes, glycerol, acetate, ethanol and methanol. More specifically, the carbon source can be selected from the group consisting of glucose; Petition 870250101536, dated 06 / 11 / 2025, pages 147 / 174 29 / 49 sucrose, glycerol, vegetable oils, methane, ethane and butane. It is a major advantage of the present invention that the cells, as described, are able to form lipids with general formula I and / or II from the simplest carbon sources, such as glucose, sucrose or glycerol, so that it is not necessary to supply longer chain carbon sources in the medium during the method, according to any aspect of the present invention. In particular, the carbon source can be selected from the group consisting of glucose, dextrose, sucrose, xylose, mannose, galactose, arabinose, monosaccharides, polysaccharides, cellulose, hemicelluloses, vegetable oils, animal fats, fatty acids, fatty acid esters, carbonaceous gases, alkanes, glycerol, acetate, ethanol and methanol.

[058] According to another aspect of the present invention, a microbial cell is provided to produce at least one lipid with general formula II from at least one carbon substrate. General Formula II wherein R1 and R2, independently of each other, comprise identical or different organic radicals, each with 5 to 13 carbon atoms, wherein the cell is a non-pathogenic cell genetically modified to introduce a DNA sequence encoding for: - Enzyme E1, a 3-(3-hydroxyalkaneyloxy)alkanoic acid (HAA) synthase, in which the amino acid sequence of E1 is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 7, SEQ ID NO: 11, SEQ ID NO: 15, and a variant thereof, with the variant exhibiting 60% sequence identity. Petition 870250101536, dated 06 / 11 / 2025, pp. 148 / 174 30 / 49 with SEQ ID NO:15. 1, 7, 11 or 15; and - Enzyme E2, a glycosyltransferase (EC 2.4), in which the amino acid sequence of E2 is selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 8, SEQ ID NO: 11, and a variant thereof, the variant having 60% sequence identity with SEQ ID NO: 11.2, 8 or 11.

[059] According to another aspect of the present invention, a method is provided for producing at least one lipid with general formula II: General Formula II wherein R1 and R2, independently of each other, are identical or different alkyl groups with 5 to 13 carbon atoms, and wherein the method comprises a contact step with at least one cell according to any aspect of the present invention with at least one carbon source.

[060] In particular, the alkyl group of R1 and / or R2 may be saturated or unsaturated. More specifically, the alkyl group of R1 and / or R2 may be a saturated alkyl radical. Even more specifically, R1 and / or R2 may be selected from the group consisting of pentyl, heptyl, nonyl, undecyl and (CH2)n-CH3 with n = 4-12.

[061] The method, according to any aspect of the present invention, can also be used to produce another lipid with general formula I from the carbon substrate, Petition 870250101536, dated 06 / 11 / 2025, pp. 149 / 174 31 / 49 General Formula I wherein R1 and R2, independently of each other, are identical or different alkyl groups with 5 to 13 carbon atoms. In particular, the alkyl group of R1 and / or R2 may be saturated or unsaturated. More specifically, the alkyl group of R1 and / or R2 may be a saturated alkyl radical. Even more specifically, R1 and / or R2 may be selected from the group consisting of pentyl, heptyl, nonyl, undecyl, tridecyl and (CH2)n-CH3 with n = 4-12.

[062] The method, according to any aspect of the present invention, can be used to produce a lipid mixture comprising the lipid with general formula I and II. In particular, the lipids with general formula I and II are produced in the ratio of 1:100, 1:90, 1:80, 1:70, 1:60, 1:50, 1:40, 1:30, 1:20, 1:10, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, 5:1, 10:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1 or 100:1. More specifically, the lipids of formula I and II may simultaneously exhibit varying lengths of alkyl chains in the R subgroup.

[063] According to yet another aspect of the present invention, the use of the cell, as per any aspect of the present invention, is provided for the production of at least one lipid with general formula I and / or II: R1 0R2 General Formula I Petition 870250101536, dated 06 / 11 / 2025, pp. 150 / 174 32 / 49 General Formula II wherein R1 and R2, independently of each other, are identical or different alkyl groups with 5 to 13 carbon atoms. In particular, the alkyl group of R1 and / or R2 may be saturated or unsaturated. More specifically, the alkyl group of R1 and / or R2 may be a saturated alkyl radical. Even more specifically, R1 and / or R2 may be selected from the group consisting of pentyl, heptyl, nonyl, undecyl, tridecyl and (CH2)n-CH3 with n = 4-12. EXAMPLES

[064] The above describes preferred embodiments which, as will be understood by those skilled in the art, may be subject to variations or modifications in design, construction or operation, without departing from the scope of the claims. Such variations, for example, are intended to be covered by the scope of the claims. EXAMPLE 1 CONSTRUCTION OF AN EXPRESSION VECTOR FOR THE rbwAB GENES OF NODE_2 OF THE PANTOEA ANANATIS PNA 99-7 STRAIN

[065] For heterologous expression of the genes rbwA Pan997 as enzyme E1 and rbwB Pan997 as enzyme E2 of the strain Pantoea ananatis PNA 99-7 NODE_2, the plasmid pACYC {PRhaRS}[rhaRS_Ec] {PRha} [rbwA_Pan997 rbwB_Pan997] {ter} was constructed. The synthetic operon composed of rbwAB_Pan997 (SEQ ID NO:3), which encodes a 3-(3'-hydroxyalkaneyloxy)alkanoic acid (HAA) synthase (RbwA, SEQ ID NO:1) and a glycosyltransferase (RbwB, SEQ ID NO:2), respectively, was cloned under the control of the rhamnose-inducible promoter Prha in the pACYC vector {PRhaRS}[rhaRS_Ec]{PRha}[rhlA_Pa rbwB_Srub], as disclosed in the example. Petition 870250101536, dated 06 / 11 / 2025, pp. 151 / 174 33 / 49 of WO2019154984, which is based on pAYCY184 (New England Biolabs, Frankfurt / Main, Germany). A terminator sequence was located downstream of the synthetic operon. The genes were amplified from synthetic DNA generated by Eurofins Genomics via PCR. The pACYC plasmid {PRhaRS}[rhaRS_Ec]{PRha}[rhlA_Pa rbwB_Srub] contains the PRha promoter cassette (SEQ ID NO: 4) and the terminator sequence (SEQ ID NO: 5), a p15A origin of replication for E. coli, and a pVS1 origin of replication for replication in P. putida KT2440. The pVS1 origin comes from the pVS1 plasmid of Pseudomonas (Itoh Y, et al.). Plasmid 1984, 11(3), 206-20). For amplification, the Q5® HighFidelity 2X Master Mix from New England Biolabs (Frankfurt / Main, Germany) was used, as per the manufacturer's instructions.In the next step, the amplified fragment was cloned into the pACYC {PRhaRS}[rhaRS_Ec] {PRha} [rhlA_Pa rbwB_Srub] vector, as disclosed in example WO2019154984, using the ApaI / PspXI restriction sites and the NEBuilder® HiFi DNA Assembly Master Mix. The assembled product was transformed into electrocompetent NEB® 10-beta E. coli cells (New England Biolabs, Frankfurt / Main, Germany). The PCR purification, cloning, and transformation procedures were performed according to the manufacturer's instructions. The correct insertion of the target genes was verified by restriction analysis, and the authenticity of the introduced DNA fragments was confirmed by DNA sequencing. The resulting plasmid was named pACYC {PRhaRS}[rhaRS_Ec]{PRha} [rbwA_Pan997 rbwB_Pan997] {ter} (SEQ ID NO:6).

[066] The P. putida KT2440 strain was transformed with the pACYC {PRhaRS}[rhaRS_Ec]{PRha} [rbwA_Pan997 rbwB_Pan997] {ter} plasmid by electroporation (Iwasaki K, et al., Biosci.). Biotechnology. Biochemistry. 1994. 58(5):851-854)) and plated on LBagar plates supplemented with kanamycin (50 pg / mL). The transformants were verified for the presence of the correct plasmid by plasmid preparation and analytical restriction analysis. The resulting strain was named BS-S-644 (P. putida KT2440 + pACYC {PRhaRS}[rhaRS_Ec] {PRha}[rbwA_Pan997 rbwB_Pan997] {ter}). Petition 870250101536, dated 06 / 11 / 2025, pages 152 / 174 34 / 49 EXAMPLE 2 CONSTRUCTION OF AN EXPRESSION VECTOR FOR PANTOEA sp. rbwAB GENES of SJZ147

[067] For heterologous expression of the genes rbwA_PanSJ as E1 enzyme and rbwB_PanSJ as E2 enzyme of Pantoea sp. The pACYC {PRhaRS}[rhaRS_Ec] {PRha}[rbwA_PanSJ rbwB_PanSJ] plasmid was constructed from SJZ147. The synthetic operon composed of rbwAB__PanSJ (SEQ ID NO:9), encoding a 3-(3'-hydroxyalkaneyloxy)alkanoic acid (HAA) synthase (RbwA, SEQ ID NO:7) and a glycosyltransferase (RbwB, SEQ ID NO:8), respectively, was cloned under the control of the rhamnose-inducible Prha promoter in the pACYC {PRhaRS}[rhaRS_Ec]{PRha}[rhlA_Pa rbwB_Srub] vector (WO2019154984), based on pAYCY184 (New England Biolabs, Frankfurt / Main, Germany). Downstream of the synthetic operon is a terminator sequence. The genes were amplified from synthetic DNA generated by Eurofins Genomics via PCR.The pACYC {PRhaRS}[rhaRS_Ec] {PRha}[rhlA_Pa rbwB_Srub] plasmid contains the PRha promoter cassette (SEQ ID NO: 4) and the terminator sequence (SEQ ID NO: 5), a p15A origin of replication for E. coli, and a pVS1 origin of replication for replication in P. putida KT2440. The pVS1 origin is derived from the Pseudomonas pVS1 plasmid (Itoh Y, et al.). Plasmid 1984, 11(3), 206-220). For amplification, the Q5® High-Fidelity 2X Master Mix from New England Biolabs (Frankfurt / Main, Germany) was used, according to the manufacturer's instructions. In the next step, the amplified fragment was cloned into the pACYC {PRhaRS}[rhaRS_Ec] {PRha}[rhlA_Pa rbwB_Srub] vector using the ApaI / PspXI restriction sites and the NEBuilder® HiFi DNA Assembly Master Mix. The assembled product was transformed into electrocompetent E. coli NEB® 10-beta cells (New England Biolabs, Frankfurt / Main, Germany). The PCR purification, cloning, and transformation procedures were performed according to the manufacturer's instructions.The correct insertion of the target genes was verified by restriction analysis, and the authenticity of the introduced DNA fragments was confirmed by DNA sequencing. The resulting plasmid was named. Petition 870250101536, dated 06 / 11 / 2025, pages 153 / 174 35 / 49 pACYC {PRhaRS}[rhaRS_Ec] {PRha} [rbwA_PanSJ rbwB_PanSJ] (SEQ ID NO:10).

[068] The P. putida KT2440 strain was transformed with the pACYC {PRhaRS}[rhaRS_Ec] {PRha} [rbwA_PanSJ rbwB_PanSJ] {ter} plasmid by electroporation (Iwasaki K, et al., Biosci.). Biotechnology. Biochemistry. 1994. 58(5):851-854)) and plated on LB-agar plates supplemented with kanamycin (50 μg / mL). The transformants were verified for the presence of the correct plasmid by plasmid preparation and analytical restriction analysis. The resulting strain was named BSS-645 (P. putida KT2440 + pACYC {PRhaRS}[rhaRS_Ec] {PRha}[rbwA_PanSJ rbwB_PanSJ] {ter}). EXAMPLE 3 CONSTRUCTION OF AN EXPRESSION VECTOR FOR THE rbwAB GENES OF THE NS381 PANTOEA STEWARTII STRAIN

[069] For heterologous expression of the genes rbwA_Pst381 as enzyme E1 and rbwB_Pst381 as enzyme E2, of the NS381 strain of Pantoea stewartii, the plasmid pACYC {PRhaRS}[rhaRS_Ec] {PRha} [rbwA_Pst381 rbwB_Pst381] {ter} was constructed. The synthetic operon composed of rbwAB_Pst381 (SEQ ID NO:13), encoding a 3-(3'-hydroxyalkaneyloxy)alkanoic acid (HAA) synthase (RbwA, SEQ ID NO:11) and a glycosyltransferase (RbwB, SEQ ID NO:12), respectively, was cloned under the control of the rhamnose-inducible Prha promoter in the pACYC {PRhaRS}[rhaRS_Ec]{PRha}[rhlA_Pa rbwB_Srub] vector (WO2019154984), based on the pACYC184 plasmid (New England Biolabs, Frankfurt / Main, Germany). Downstream of the synthetic operon is a terminator sequence. The genes were amplified from synthetic DNA generated by Eurofins Genomics via PCR.The pACYC {PRhaRS}[rhaRS_Ec] {PRha}[rhlA_Pa rbwB_Srub] plasmid contains the PRha promoter cassette (SEQ ID NO: 4) and the terminator sequence (SEQ ID NO: 5), a p15A origin of replication for E. coli, and a pVS1 origin of replication for replication in P. putida KT2440. The pVS1 origin is derived from the Pseudomonas pVS1 plasmid (Itoh Y, et al.). Plasmid 1984, 11(3), 206-220). For amplification, the Q5® High-Fidelity 2X Master Mix from New England Biolabs was used. Petition 870250101536, dated 06 / 11 / 2025, pp. 154 / 174 36 / 49 (Frankfurt / Main, Germany), according to the manufacturer's manual. In the next step, the amplified fragment was cloned into the pACYC {PRhaRS}[rhaRS_Ec] {PRha}[rhlA_Pa rbwB_Srub] vector using the ApaI / PspXI restriction sites and NEBuilder® HiFi DNA Assembly Master Mix. The assembled product was transformed into electrocompetent E. coli NEB® 10-beta cells (New England Biolabs, Frankfurt / Main, Germany). PCR purification, cloning, and transformation procedures were performed according to the manufacturer's manual. Correct insertion of the target genes was verified by restriction analysis, and the authenticity of the introduced DNA fragments was confirmed by DNA sequencing. The resulting plasmid was named pACYC {PRhaRS}[rhaRS_Ec] {PRha}[rbwA_Pst381 rbwB_Pst381] {ter} (SEQ ID NO:14).

[070] The P. putida KT2440 strain was transformed with the pACYC {PRhaRS}[rhaRS_Ec] {PRha} [rbwA_Pst381 rbwB_Pst381] {ter} plasmid by electroporation (Iwasaki K, et al., Biosci.). Biotecnologia. Biochem. 1994. 58(5):851-854)) and plated on LB-agar plates supplemented with kanamycin (50 μg / mL). The transformants were verified for the presence of the correct plasmid by plasmid preparation and analytical restriction analysis. The resulting strain was named BS-S-646 (P. putida KT2440 + pACYC {PRhaRS}[rhaRS_Ec] {PRha}[rbwA_Pst381 rbwB_Pst381] {ter}). EXAMPLE 4 CONSTRUCTION OF AN EXPRESSION VECTOR FOR THE rhlA GENE OF P. AERUGINOSA AND THE rbwB GENE OF THE PANTOEA ANANATIS STRAIN PNA 99-7 NODE_2

[071] For heterologous expression of the rhlA_Pa genes as an E1 enzyme and rbwB_Pan997 as an E2 enzyme, from the Pantoea ananatis PNA 99-7 NODE_2 strain, the pACYC {PRhaRS}[rhaRS_Ec]{PRha}[rhlA_Pa rbwB_Pan997] {ter} plasmid was constructed. The synthetic operon composed of rhlA_Pa (SEQ ID NO:17), which encodes a 3-(3-hydroxyalkaneyloxy)alkanoic acid (HAA) synthase (RhlA, SEQ ID NO:16) and a glycosyltransferase (RbwB, SEQ ID NO: 2), respectively, was cloned. Petition 870250101536, dated 06 / 11 / 2025, pp. 155 / 174 37 / 49 under the control of the rhamnose-inducible Prha promoter in the pACYC {PRhaRS}[rhaRS_Ec]{PRha}[rhlA_Pa rbwB_Srub] vector (WO2019154984), based on the pACYC184 plasmid (New England Biolabs, Frankfurt / Main, Germany). Downstream of the synthetic operon is a terminator sequence. The rbwB_Pan997 gene was synthetically generated by Eurofins Genomics as a DNA fragment. The pACYC {PRhaRS}[rhaRS_Ec] {PRha}[rhlA_Pa rbwB_Srub] plasmid contains the PRha promoter cassette (SEQ ID NO: 4) and the terminator sequence (SEQ ID NO: 5), a p15A origin of replication for E. coli, and a pVS1 origin of replication for replication in P. putida KT2440. The pVS1 origin is derived from the Pseudomonas pVS1 plasmid (Itoh Y, et al.). Plasmid 1984, 11(3), 206-20). The synthetic DNA fragment was cloned into the pACYC {PRhaRS}[rhaRS_Ec]{PRha}[rhlA_Pa rbwB_Srub] vector using the PspXI restriction site and NEBuilder® HiFi DNA Assembly Master Mix. The assembled product was transformed into E. coli cells.coli NEB® 10-beta electrocompetent plasmids (New England Biolabs, Frankfurt / Main, Germany). PCR purification, cloning, and transformation procedures were performed according to the manufacturer's manual. Correct insertion of target genes was verified by restriction analysis, and the authenticity of the introduced DNA fragments was confirmed by DNA sequencing. The resulting plasmid was named pACYC {PRhaRS}[rhaRS_Ec] {PRha} [rhlA_Pa rbwB_Pan997] {ter} (SEQ ID NO:17).

[072] The P. putida KT2440 strain was transformed with the pACYC {PRhaRS}[rhaRS_Ec] {PRha} [rhlA_Pa rbwB_Pan997] {ter} plasmid by electroporation (Iwasaki K, et al., Biosci.). Biotechnology. Biochemistry 1994. 58(5):851-854)) and plated on LBagar plates supplemented with kanamycin (50 pg / mL). The transformants were checked for the presence of the correct plasmid by plasmid preparation and analytical restriction analysis. The resulting strain was named BS-S-647 (P.putida KT2440 + pACYC {PRhaRS}[rhaRS_Ec]{PRha}[rhlA_Pa rbwB_Pan997] {ter}). EXAMPLE 5 CONSTRUCTION OF AN EXPRESSION VECTOR FOR THE rhlA GENE Petition 870250101536, dated 06 / 11 / 2025, pp. 156 / 174 38 / 49 OF P. AERUGINOSA AND PANTOEA sp. rbwB GENE of SJZ147

[073] For heterologous expression of the rhlA_Pa genes as an E1 enzyme and rbwB_PanSJ as an E2 enzyme in PANTOEA sp. SJZ147: the pACYC {PRhaRS}[rhaRS_Ec] {PRha} [rhlA_Pa rbwB_PanSJ] {ter} plasmid was constructed. The synthetic operon, composed of rhlA_Pa (SEQ ID NO:18), which encodes a 3-(3-hydroxyalkaneyloxy)alkanoic acid (HAA) synthase (RhlA, SEQ ID NO:15), and a glycosyltransferase (RbwB, SEQ ID NO:8), respectively, was cloned under the control of the rhamnose-inducible promoter Prha in the pACYC vector {PRhaRS}[rhaRS_Ec]{PRha}[rhlA_Pa rbwB_Srub] (WO2019154984), based on pAYCY184 (New England Biolabs, Frankfurt / Main, Germany). Downstream of the synthetic operon is a terminator sequence. The rbwB_PanSJ gene was synthetically generated by Eurofins Genomics as a DNA fragment. The pACYC plasmid {PRhaRS}[rhaRS_Ec] {PRha}[rhlA_Pa rbwB_Srub] contains the PRha promoter cassette (SEQ ID NO: 4) and the terminator sequence (SEQ ID NO: 5), a p15A replication origin for E.E. coli and a pVS1 origin of replication for replication in P. putida KT2440. The pVS1 origin is derived from the Pseudomonas pVS1 plasmid (Itoh Y, et al.). Plasmid 1984, 11(3), 206-220). The synthetic DNA fragment was cloned into the pACYC {PRhaRS}[rhaRS_Ec]{PRha}[rhlA_Pa rbwB_Srub] vector using the PspXI restriction site and NEBuilder® HiFi DNA Assembly Master Mix. The assembled product was transformed into electrocompetent E. coli NEB® 10-beta cells (New England Biolabs, Frankfurt / Main, Germany). PCR purification, cloning, and transformation procedures were performed according to the manufacturer's instructions. Correct insertion of the genes of interest was verified by restriction analysis, and the authenticity of the introduced DNA fragments was confirmed by DNA sequencing. The resulting plasmid was named pACYC {PRhaRS}[rhaRS_Ec] {PRha} [rhlA_Pa rbwB_PanSJ] {ter} (SEQ ID NO:19).

[074] The P. putida KT2440 strain was transformed with the pACYC {PRhaRS}[rhaRS_Ec] {PRha} [rhlA_Pa rbwB_PanSJ] {ter} plasmid by electroporation (Iwasaki K, et al., Biosci.). Biotechnology. Biochemistry 1994. 58(5):851-854)) and plated on Petition 870250101536, dated 06 / 11 / 2025, pages 157 / 174 39 / 49 LBagar plates supplemented with kanamycin (50 pg / mL). Transformants were checked for the presence of the correct plasmid by plasmid preparation and analytical restriction analysis. The resulting strain was named BS-S648 (P. putida KT2440 + pACYC {PRhaRS}[rhaRS_Ec] {PRha} [rhlA_Pa rbwB_PanSJ] {ter}). EXAMPLE 6 CONSTRUCTION OF AN EXPRESSION VECTOR FOR THE rhlA GENE OF P. AERUGINOSA AND THE rbwB GENE OF THE NS381 STRAIN OF PANTOEA STEWARTII

[075] For the heterologous expression of the rhlA_Pa genes as an E1 enzyme and rbwB_Pst381 as an E2 enzyme of the NS381 strain of Pantoea stewartii, the pACYC plasmid was constructed {PRhaRS}[rhaRS_Ec]{PRha}[rhlA_Pa rbwB_Pst381] {ter}. The synthetic operon, composed of rhlA_Pa (SEQ ID NO: 20), which encodes a 3-(3-hydroxyalkaneyloxy)alkanoic acid (HAA) synthase (RhlA, SEQ ID NO: 15) and a glycosyltransferase (RbwB, SEQ ID NO: 12), respectively, was cloned under the control of the rhamnose-inducible promoter Prha into the pACYC vector {PRhaRS}[rhaRS_Ec]{PRha}[rhlA_Pa rbwB_Srub] (WO2019154984), based on pAYCY184 (New England Biolabs, Frankfurt / Main, Germany). Downstream of the synthetic operon is a terminator sequence. The rbwB_Pst381 gene was synthetically generated by Eurofins Genomics as a DNA fragment.The pACYC {PRhaRS}[rhaRS_Ec] {PRha} [rhlA_Pa rbwB_Srub] plasmid contains the PRha promoter cassette (SEQ ID NO: 4) and the terminator sequence (SEQ ID NO: 5), a p15A origin of replication for E. coli, and a pVS1 origin of replication for replication in P. putida KT2440. The pVS1 origin is derived from the Pseudomonas pVS1 plasmid (Itoh Y, et al.). Plasmid 1984, 11(3), 206-220). The synthetic DNA fragment was cloned into the pACYC {PRhaRS}[rhaRS_Ec] {PRha} [rhlA_Pa rbwB_Srub] vector using the PspXI restriction site and NEBuilder® HiFi DNA Assembly Master Mix. The assembled product was transformed into electrocompetent NEB® 10-beta E. coli cells (New England Biolabs, Frankfurt / Main, Germany). The PCR purification, cloning, and transformation procedures were performed according to the manufacturer's instructions. Petition 870250101536, dated 06 / 11 / 2025, pages 158 / 174 40 / 49 The correct insertion of the target genes was verified by restriction analysis, and the authenticity of the introduced DNA fragments was confirmed by DNA sequencing. The resulting plasmid was named pACYC {PRhaRS}[rhaRS_Ec] {PRha} [rhlA_Pa rbwB_Pst381] {ter} (SEQ ID NO: 21).

[076] The P. putida KT2440 strain was transformed with the pACYC {PRhaRS}[rhaRS_Ec] {PRha} [rhlA_Pa rbwB_Pst381] {ter} plasmid by electroporation (Iwasaki K, et al., Biosci.). Biotechnology. Biochemistry. 1994. 58(5):851-854)) and plated on LBagar plates supplemented with kanamycin (50 pg / mL). The transformants were verified for the presence of the correct plasmid by plasmid preparation and analytical restriction analysis. The resulting strain was named BS-S-649 (P. putida KT2440 + pACYC {PRhaRS}[rhaRS_Ec]{PRha}[rhlA_Pa rbwB_Pst381] {ter}). EXAMPLE 7 PRODUCTION OF RUBIWETTIN WITH DERIVATIVES OF P. PUTIDA

[077] For the production of rubiwettin, we used the BioLector I system (Beckman Coulter Life Sciences, Baesweiler, Germany). The following strains were analyzed: BS-S-644: P. putida KT2440 + pACYC {PRhaRS}[rhaRS_Ec]{PRha}[rbwA_Pan997 rbwB_Pan997] {ter} BS-S-645: P. putida KT2440 + pACYC {PRhaRS}[rhaRS_Ec]{PRha}[rbwA_PanSJ rbwB_PanSJ] {ter} BS-S-646: P. putida KT2440 + pACYC {PRhaRS}[rhaRS_Ec]{PRha}[rbwA_Pst381 rbwB_Pst381] {ter} BS-S-647: P. putida KT2440 + pACYC {PRhaRS}[rhaRS_Ec]{PRha}[rhlA_Pa rbwB_Pan997] {ter} BS-S-648: P. putida KT2440 + pACYC {PRhaRS}[rhaRS_Ec]{PRha}[rhlA_Pa rbwB_PanSJ] {ter} BS-S-649: P. putida KT2440 + pACYC {PRhaRS}[rhaRS_Ec]{PRha}[rhlA_Pa rbwB_Pst381] {ter}

[078] Pre-cultures were inoculated from a glycerol stock in a Petition 870250101536, dated 06 / 11 / 2025, pp. 159 / 174 41 / 49 FlowerPlate without optodes (48-well MTP, flower shape, Beckman Coulter Life Sciences, Baesweiler, Germany, Art.-No.:). MTP-48-B) with 1 ml of inoculation medium (autoclaved: 4.4 g / L Na2HPO4* 2 H2O, 1.5 g / L KH2PO4, 1 g / L NH4Cl, 10 g / L yeast extract, sterilized separately: 20 g / L glucose, 0.2 g / L MgSO4 * 7 H2O, 0.006 g / L FeCl3, 0.015 g / L CaCl2, 1 ml / L trace element solution SL6 (sterile filtered: 0.3 g / L H3BO3, 0.2 g / L CoCh x 6 H2O, 0.1 g / L ZnSO4 x 7 H2O, 0.03 g / L MnCl2 x 4 H2O, 0.01 g / L CuCl2 x 2 H2O, 0.03 g / L Na2MoO4 x 2 H2O, 0.02 g / L NiCh x 6 H2O) supplemented with kanamycin (50 pg / mL). The pre-cultures were incubated for approximately 19 hours at 1000 rpm and 32 °C, with a relative humidity of 85%.

[079] The main crops were inoculated with the pre-culture to achieve a Initial OD600 of 0.5 on a FlowerPlate with pH and dissolved oxygen optodes (48-well MTP, flower shape, Beckman Coulter Life Sciences, Baesweiler, Germany, Art.-No.: M2P-MTP-48-BOH1) in M12-FIT medium (2.2 g / L of (N^hSO4, 0.02 g / L of NaCl, 0.4 g / L of MgSO4 x 7 H2O, 0.05 g / L of CaCl2 x 2 H2O, 3 g / L of KH2PO4, 8.51 g / L of Na2HPO4*2 H2O, 5 g / L of glucose, 25 g / L of maltodextrin (C*Dry MD 01955), 10 mL / L of M12 trace element solution (sterilely filtered: 0.2 g / L of ZnSO4 x 7 H2O, 0.1 g / L MnCk x 4 H2O, 1.5 g / L Na3-Citrate x 2 H2O, 0.1 g / L CuSO4 x 5 H2O, 0.002 g / L NiC^ x 6 H2O, 0.003 g / L Na2MoO4 x 2 H2O, 0.03 g / L H3BO3, 1 g / L FeSO4 x 7 H2O)) supplemented with kanamycin (50 pg / mL). The main cultures were incubated for approximately 50 hours at 800 rpm and 32 °C, with a relative humidity of 85%.

[080] Feeding was initiated with the addition of 1% (v / v) sterile filtered amyloglucosidase solution (100000 U / L) from Aspergillus niger, triggered by the pO2 peak, which indicates the end of the batch phase. The expression of the target genes was induced simultaneously with 0.2% (w / v). After cultivation, it was possible to detect a concentration (mg / L) of rubiwettins with different chain lengths (see Table 1).

[081] Table 1: Concentrations of rubiwettins obtained with different strains of Petition 870250101536, dated 06 / 11 / 2025, pages 160 / 174 42 / 49 P. putida. The concentrations of the individual rubiwettin species are indicated, along with their respective chain lengths and degree of saturation of the 3-hydroxyfatty acid moieties. mg / l mg / l mg / l mg / l mg / l mg / l mg / l mg / l mg / l mg / l mg / l strain 1GL- C8- C8 1GL- C8- C10 1RL- C10- C10: 1 1GL- C10- C10 1GLC10- C12: 1 1GL C10C12 1GL- C12- C12:1 1GL- C12- C12 1GL- C10- C14 1GLC10- C16: 1 1GL C10C16 P. putida + pACYCAT h-5 0 0 0 0 0 0 0 0 0 0 0 P. putida + pACYCAT h-5 0 0 0 0 0 0 0 0 0 0 0 P. putida + pACYCAT h-5 0 0 0 0 0 0 0 0 0 0 0 BS-S-644 0 25 0 413 39 66 0 0 0 0 0 BS-S-644 0 24 0 383 31 59 0 0 0 0 0 BS-S-644 0 23 0 398 34 66 0 0 0 0 0 BS-S-645 0 0 0 0 0 0 0 0 0 0 0 BS-S-645 0 0 0 0 0 0 0 0 0 0 0 BS-S-645 0 0 0 0 0 0 0 0 0 0 0 BS-S-646 31 334 19 2724 218 365 0 0 0 0 0 BS-S-646 34 317 21 2697 204 352 0 0 0 0 0 Petition 870250101536, dated 06 / 11 / 2025, pages 161 / 174 43 / 49 BS-S-646 27 288 0 2638 194 350 0 0 0 0 0 BS-S-647 0 403 20 2742 82 126 0 0 0 0 0 BS-S-647 25 346 24 1915 51 86 0 0 0 0 0 BS-S-647 28 358 28 2025 65 82 0 0 0 0 0 BS-S-648 108 973 42 2979 175 201 0 0 0 0 0 BS-S-648 105 978 43 2989 161 179 0 0 0 0 0 BS-S-648 107 1025 42 3165 172 199 0 0 0 0 0 BS-S-649 118 1095 48 3855 167 205 0 0 0 0 0 BS-S-649 120 1104 57 3991 202 224 0 0 0 0 0 BS-S-649 127 1154 57 4117 197 235 0 0 0 0 0

[082] Table 2: Proportions of individual rubiwettin species produced with different strains of P. putida. The proportions of individual rubiwettin species, with their respective chain lengths and degree of saturation of the 3-hydroxyfatty acid moieties, are presented as a percentage of the total rubiwettins. % % % % % % % % % % % 1GL 1GL 1RL- 1GL- 1GL- 1GL- 1GL- 1GL- 1GL- 1GL- 1GL- strain -C8- -C8- C10- C10- C10- C10- C12- C12- C10- C10- C10- C8 C10 C10:1 C10 C12:1 C12 C12:1 C12 C14 C16:1 C16 P. putida + pACYCA Th-5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Petition 870250101536, dated 06 / 11 / 2025, pages 162 / 174 44 / 49 P. putida + pACYCA Th-5 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 P.putida + pACYCA Th-5 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 BS-S-644 0,0 4,1 0,0 68,7 6,5 11,0 0,0 0,0 0,0 0,0 0,0 BS-S-644 0,0 4,3 0,0 70,1 5,7 10,8 0,0 0,0 0,0 0,0 0,0 BS-S-644 0,0 4,0 0,0 70,0 6,0 11,7 0,0 0,0 0,0 0,0 0,0 BS-S-645 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 BS-S-645 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 BS-S-645 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 BS-S-646 0,8 8,9 0,5 72,8 5,8 9,8 0,0 0,0 0,0 0,0 0,0 BS-S-646 0,9 8,6 0,6 73,3 5,5 9,6 0,0 0,0 0,0 0,0 0,0 BS-S-646 0,7 8,1 0,0 74,1 5,5 9,8 0,0 0,0 0,0 0,0 0,0 BS-S-647 0,0 11,6 0,6 79,0 2,4 3,6 0,0 0,0 0,0 0,0 0,0 BS-S-647 1,0 13,6 0,9 75,2 2,0 3,4 0,0 0,0 0,0 0,0 0,0 BS-S-647 1,0 13,3 1,0 75,4 2,4 3,1 0,0 0,0 0,0 0,0 0,0 BS-S-648 2,4 21,5 0,9 66,0 3,9 4,4 0,0 0,0 0,0 0,0 0,0 BS-S-648 2,3 21,8 1,0 66,5 3,6 4,0 0,0 0,0 0,0 0,0 0,0 BS-S-648 2,3 21,6 0,9 66,6 3,6 4,2 0,0 0,0 0,0 0,0 0,0 BS-S-649 2,1 19,8 0,9 69,6 3,0 3,7 0,0 0,0 0,0 0,0 0,0. Petição 870250101536, de 06 / 11 / 2025, pág. 163 / 174 45 / 49 BS-S-649 2.1 19.2 1.0 69.4 3.5 3.9 0.0 0.0 0.0 0.0 0.0 BS-S-649 2.1 19.5 1.0 69.5 3.3 4.0 0.0 0.0 0.0 0.0 0.0

[083] The results show that the use of SEQ-IDs 1, 7 and 11 of Pantoea sp. As E1, replacing the SEQ-ID of Pseudomonas aeruginosa, leads to a shift of rubiwettin species from C10:0-C12:1 and C10:0-C12:0 to C8:0-C10:0. Rubiwettin species with shorter 3-hydroxyfatty acid chains will exhibit different application profiles than species with longer 3-hydroxyfatty acid chains. EXAMPLE 7 CONSTRUCTION OF EXPRESSION VECTORS FOR THE rhlA GENE OF P. AERUGINOSA AND THE rbwB GENE OF SERRATIA RUBIDAEA

[084] For heterologous expression of the rhlA_Pa gene as an E1 enzyme in combination with the rbwB_Srub gene from Serratia rubidaea as an E2 enzyme, the genes were placed under the control of the rhamnose-inducible promoter Prha using the pACYC5 vector backbone, as described in patent WO2019154984, example 3. EXAMPLE 8 PRODUCTION OF RUBIWETTIN WITH DERIVATIVES OF P. PUTIDA

[085] For the production of rubiwettin, we used the BioLector I system (Beckman Coulter Life Sciences, Baesweiler, Germany). The following strains were analyzed: BS-S-368 P. putida KT2440 + pACYC_rhlA_Pa_rbwB_Srub (Example 7) BS-S-647 P. putida KT2440 + pACYC {PRhaRS}[rhaRS_Ec]{PRha}[rhlA_Pa rbwB_Pan997] {ter} (Example 4) BS-S-648 P. putida KT2440 + pACYC {PRhaRS}[rhaRS_Ec]{PRha}[rhlA_Pa rbwB_PanSJ] {ter} (Example 5) BS-S-649 P. putida KT2440 + pACYC {PRhaRS}[rhaRS_Ec]{PRha}[rhlA_Pa rbwB_Pst381] {ter} (Example 6) Petition 870250101536, dated 06 / 11 / 2025, pages 164 / 174 46 / 49

[086] Pre-cultures were inoculated from a glycerol stock in a FlowerPlate without optodes (48-well MTP, flower shape, Beckman Coulter Life Sciences, Baesweiler, Germany, Art.-No.: MTP-48-B) with 1 ml of inoculation medium (autoclaved: 4.4 g / L Na2HPO4 * 2 H2O, 1.5 g / L KH2PO4, 1 g / L NH4Cl, 10 g / L yeast extract, separately sterilized: 20 g / L glucose, 0.2 g / L MgSO4 * 7 H2O, 0.006 g / L FeCl3, 0.015 g / L CaCl2, 1 ml / L trace element solution SL6 (sterile filter: 0.3 g / L H3BO3, 0.2 g / L CoCl2 x 6 H2O, 0.1 g / L ZnSO4 x 7 The pre-cultures were prepared using a mixture of H2O, 0.03 g / L MnCl2 x 4H2O, 0.01 g / L CuCl2 x 2 H2O, 0.03 g / L Na2MoO4 x 2 H2O, and 0.02 g / L NiCl2 x 6 H2O) supplemented with kanamycin (50 μg / mL). The pre-cultures were incubated for approximately 19 ha at 1000 rpm and 32 °C, with a relative humidity of 85%.

[087] The main cultures were inoculated with the pre-culture to achieve an initial optical density (OD600) of 0.5 in a FlowerPlate with pH and dissolved oxygen optodes (48-well MTP plate, flower shape, Beckman Coulter Life Sciences, Baesweiler, Germany, Art.-No. :) M2P-MTP-48-BOH1) in M12-FIT medium (2.2 g / L (NH4)2SO4, 0.02 g / L NaCl, 0.4 g / L MgSO4 x 7H2O, 0.05 g / L CaCl2 x 2H2O, 3 g / L KH2PO4, 8.51 g / L Na2HPO4*2H2O, 5 g / L glucose, 25 g / L maltodextrin (C*Dry MD 01955), 10 mL / L trace element solution M12 (sterilely filtered: 0.2 g / L ZnSO4 x 7 H2O, 0.1 g / L MnCl2 x 4H2O, 1.5 g / L Na3-Citrate x 2 H2O, 0.1 g / L CuSO4 x 5 H2O, 0.002 g / L NiCl2 x 6 H2O, 0.003 g / L Na2MoO4 x 2 H2O, 0.03 g / L H3BO3, 1 g / L FeSO4 x 7 H2O) supplemented with kanamycin (50 pg / mL). The main cultures were incubated for approximately 50 hours at 800 rpm, 32 °C and 85% relative humidity.

[088] Feeding begins with the addition of 1% (v / v) sterile filtered amyloglucosidase solution (100000 U / L) from Aspergillus niger, starting at the pO2 peak, which indicates the end of the batch phase. The expression of the target genes was induced simultaneously with 0.2% (w / v). After cultivation, it was possible to detect a concentration (mg / L) of rubiwetins with different chain lengths (see Table 3). Petition 870250101536, dated 06 / 11 / 2025, pages 165 / 174 47 / 49

[089] Table 3: Rubiwetin concentrations obtained with different strains of P. putida. The concentrations of the individual rubiwetin species are indicated, along with their respective chain lengths and degree of saturation of the 3-hydroxylated fatty acid moieties. mg / l mg / l mg / l mg / l mg / l mg / l mg / l mg / l mg / l mg / l mg / l strain 1GL -C8- C8 1GL -C8- C10 1RLC10- C10: 1 1GL - C10- C10 1GLC10- C12: 1 1GL C10C12 1GLC12- C12: 1 1GL C12C12 1GL- C10- C14 1GLC10- C16: 1 1GL- C10- C16 BS-S-368 10 125 12 1073 27 41 0 0 0 0 0 BS-S-368 9 111 13 1175 25 45 0 0 0 0 0 BS-S-368 9 131 12 1333 23 60 0 0 0 0 0 BS-S-647 0 403 20 2742 82 126 0 0 0 0 0 BS-S-647 25 346 24 1915 51 86 0 0 0 0 0 BS-S-647 28 358 28 2025 65 82 0 0 0 0 0 BS-S-648 108 973 42 2979 175 201 0 0 0 0 0 BS-S-648 105 978 43 2989 161 179 0 0 0 0 0 BS-S-648 107 102 5 42 3165 172 199 0 0 0 0 0 BS-S-649 118 109 5 48 3855 167 205 0 0 0 0 0 BS-S-649 120 110 4 57 3991 202 224 0 0 0 0 0 BS-S-649 127 115 4 57 4117 197 235 0 0 0 0 0 Petition 870250101536, dated 06 / 11 / 2025, pages 166 / 174 48 / 49

[090] The results show that the use of SEQ ID NO: 2, SEQ ID NO: 6 or SEQ ID NO: 12 of this application, originating from Pantoea sp., as enzyme E2 instead of SEQ ID NO: 4 of WO2019154984, originating from Serratia rubidaea, led to the production of higher quantities of rubiwetins. EXAMPLE 9 Quantification of rubiwettines by HPLC

[091] The quantification of R1 and RG1 lipids was performed using HPLC. Using a displacement pipette (Combitip), 400 µl of npropanol were introduced into a 2 ml reaction tube, which was immediately closed to minimize evaporation. Then, 400 µl of fermentation broth were added. After stirring for 1 minute in a Retsch mill at a frequency of 30 Hz, the resulting crude extract mixture was centrifuged for 5 minutes at 13,000 rpm, sterilely filtered with a 0.2 µm PVDF filter, and 800 µl of the clear supernatant were transferred to an HPLC vial. Further dilutions of the cell broth were performed in 55% (v / v) propanol. Samples were stored at -20 °C before measurement.

[092] For lipid detection and quantification, an evaporative light scattering detector (Sedex LT-ELSD Model 85LT) was used. Measurement was performed using the Agilent Technologies 1200 Series system (Santa Clara, California) and a Zorbax SB-C8 Rapid Resolution column (4.6 x 150 mm, 3.5 µm, Agilent). The injection volume was 5.0 µl and the run time was 20 minutes. Mobile phase A: 0.1% aqueous solution of TFA (trifluoroacetic acid); mobile phase B: methanol. The column temperature was 40 °C. ELSD (detector temperature 60 °C) and DAD (diode array, 210 nm) were used as detectors.

[093] Gradient:

[094] Table 4: Gradient. ,____________________________________ t [minutes] Flow [ml / min] Petition 870250101536, dated 06 / 11 / 2025, pp. 167 / 174 49 / 49 0.00 70% 1.00 15.00 100% 1.00 15.01 70% 1.00 20.00 70% 1.00

[095] The gradient used starts with 70% B in A up to 100% B in 15 minutes, at a flow rate of 1 mL / min, followed by 5 minutes of re-equilibration with 70% B in A (see Table 2). Reference materials were used whose identity and purity were verified by HPLC-MS / MS and NMR. Petition 870250101536, dated 06 / 11 / 2025, pp. 168 / 174

Claims

1 / 4 CLAIMS 1. Microbial cell for producing at least one lipid of general formula II from at least one carbon substrate characterized by comprising: General Formula II wherein R1 and R2, independently of each other, comprise identical or different organic radicals, each with 5 to 13 carbon atoms, wherein the cell is a non-pathogenic cell genetically modified to increase the heterologous expression, relative to the wild-type cell, of: - Enzyme E1, a 3-(3-hydroxyalkaneyloxy)alkanoic acid (HAA) synthase, comprising SEQ ID NO: 1, SEQ ID NO: 7, SEQ ID NO: 11, SEQ ID NO: 15 or a variant thereof, wherein the variant comprises 60% sequence identity with SEQ ID NO: 1, 7, 11 or 15; e - Enzyme E2, a glycosyltransferase (EC 2.4) comprising SEQ ID NO: 2, SEQ ID NO: 8, or SEQ ID NO: 12 or a variant thereof, wherein the variant comprises 60% sequence identity with SEQ ID NO: 2, 8, or 12.

2. Cell according to claim 1, characterized by comprising a lipid with general formula II, wherein the radical R is a saturated alkyl radical.

3. Cell according to claim 2, characterized by comprising an alkyl radical selected from the group consisting of pentyl, heptyl, nonyl, undecyl and tridecyl.

4. Cell, according to any one of claims 1 to 3, characterized by producing an additional lipid with general formula I from Petition 870250101536, dated 06 / 11 / 2025, page 169 / 174 2 / 4 carbon substrate, General Formula I wherein R1 and R2, independently of each other, comprise identical or different organic radicals, each with 5 to 13 carbon atoms.

5. Cell according to claim 4, characterized by comprising a lipid with general formula I, wherein the radical R is a saturated alkyl radical.

6. A cell, according to any one of claims 1 to 5, characterized in that it is used with a carbon source selected from the group consisting of glucose, dextrose, sucrose, xylose, mannose, galactose, arabinose, monosaccharides, polysaccharides, cellulose, hemicelluloses, vegetable oils, animal fats, fatty acids, fatty acid esters, carbonaceous gases, alkanes, glycerol, acetate, ethanol and methanol.

7. A cell, according to any one of claims 1 to 6, characterized by being selected from the group consisting of Acinetobacter sp., Bacillus sp., Brevibacterium sp., Burkholderia sp., Chlorella sp., Clostridium sp., Corynebacterium sp., cyanobacteria, Escherichia sp., Pseudomonas sp., Klebsiella sp., Salmonella sp., Rhizobium sp., Saccharomyces sp., Pichia sp. and Nostoc sp.

8. A cell, according to any one of claims 1 to 7, characterized by being selected from the group consisting of Bacillus subtilis, Burkholderia thailandensis, Corynebacterium glutamicum, E. coli, Klebsiella oxytoca, Pseudomonas fluorescens, Pseudomonas putida, Pseudomonas stutzeri, Rhizobium meliloti, Saccharomyces cerevisiae and Pichia pastoris.

9. Method for producing at least one lipid with general formula II and / or general formula I characterized by comprising the production of a lipid with General Formula II and General Formula I: Petition 870250101536, dated 06 / 11 / 2025, page 170 / 174 3 / 4 General Formula II, General Formula I wherein R1 and R2, independently of each other, comprise identical or different organic radicals, each with 5 to 13 carbon atoms, and wherein the method comprises a contact step of at least one cell, as defined in any one of claims 1 to 8, with at least one carbon source.

10. Method according to claim 9, characterized by comprising a carbon source selected from the group consisting of glucose, dextrose, sucrose, xylose, mannose, galactose, arabinose, monosaccharides, polysaccharides, cellulose, hemicelluloses, vegetable oils, animal fats, fatty acids, fatty acid esters, carbonaceous gases, alkanes, glycerol, acetate, ethanol and methanol.

11. Use of the cell, according to any one of claims 1 to 8, characterized by comprising the production of at least one lipid with general formula I and / or general formula II: Petition 870250101536, dated 06 / 11 / 2025, pp. 171 / 174 4 / 4 General Formula II, General Formula I wherein R1 and R2, independently of each other, comprise identical or different organic radicals, each with 5 to 13 carbon atoms. Petition 870250101536, dated 06 / 11 / 2025, pp. 172 / 174